Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Paramedic Guide - Sunnybrook Centre for Prehospital Medicine
Document related concepts
Transcript
Paramedic Guide Version 1.3 ▪ March 2014 77 Brown’s Line, Suite 100 Toronto, Ontario M8W 3S2 telephone 416-667-2200 ▪ 1-866-675-3782 fax 416-667-9776 ▪ 1-866-762-7201 web www.prehospitalmedicine.ca Maud Huiskamp Senior Manager Regional Base Hospital Program E: [email protected] O: 416-667-2200, ext. 409 Jim Summers, Manager Professional Standards & Compliance E: [email protected] O: 416-667-2200, ext. 205 Sioban Kennedy, Manager Paramedic Practice E: [email protected] O: 416-667-2200, ext. 212 Sue Thomson, Manager Paramedic Practice E: [email protected] O: 416-667-2200, ext. 210 Scott Gorsline, Manager Paramedic Practice E: [email protected] O: 416-667-2200, ext. 222 Reuven Dichter, Lead Faculty E: [email protected] O: 416-667-2200, ext. 202 The Emergency Health Services Branch of the Ministry of Health and Long Term Care Version 3.1 of the ALS Patient Care Standards will now be the standard of care. Dr. Richard Verbeek, Medical Director for the Toronto Paramedic Program, was the lead medical editor of this project. These standards contain updated medical directives for Primary and Advanced Care Paramedics. Intro To: Sunnybrook Regional Base Hospital Paramedics and Affiliates Sheldon Cheskes Richard Verbeek BSc, MD, CCFP(EM), FCFP MD, CCFP(EM), FCFP MD CM, FRCFC Medical Director, Beausoleil/ Muskoka/Rama/Simcoe Phone: 416-667-2200 ext. 0 Medical Director Peel/Halton Phone: 416-667-2200 ext. 0 Medical Director Toronto Phone: 416-667-2203 [email protected] [email protected] [email protected] This guide is for paramedic reference only and does not always accurately reflect the current scope of practice authorized within each service. Paramedics are to refer to their letter of certification for currently authorized medications and procedures. Note: This paramedic guide contains content from the Ministry of Health and Long-Term Care Advanced Life Support Patient Care Standards, 3.1, dated November 2013. Please refer to www.prehospitalmedicine.ca to access the full document. © 2014 by the Sunnybrook Centre for Prehospital Medicine 77 Brown’s Line, Suite 100 Toronto, ON M8W 3S2 ACP Paul Hoogeveen Special Events These patient care standards and guidelines include significant advances to the paramedic scope of practice since they were last published in 2007. Paramedics are dedicated and distinct professional healthcare providers who make complex medical decisions about their patients. Patients are now receiving an unprecedented high level of prehospital care that is becoming increasingly integrated with the larger medical community including acute care in hospitals, public health care and community access care. PCP The charts on the following pages summarize the medications and advanced procedures for all services under Sunnybrook. Please refer to your Sunnybrook letter of certification and medical directives for your specific scope of practice authorized within your service(s). Notes This material has been prepared and developed by Sunnybrook Centre for Prehospital Medicine and the Regional Base Hospital. Reproduction of any part of this material, written or electronic, in any form, without the written consent of Sunnybrook Centre for Preshospital Medicine is forbidden. Introduction Scope of Practice — ACP The checklists for Scope of Practice are for paramedic reference only and might not accurately reflect the current scope of practice within specific services. Drug List Acetaminophen Adenosine Amiodarone ASA Atropine Dextrose Dimenhydrinate (Gravol) Diphenhydramine (Benadryl) Dopamine Epinephrine 1:10,000 Epinephrine 1:1000 Fentanyl Glucagon Ibuprofen Ketorolac (Toradol) Lidocaine Midazolam Morphine Naloxone Nitroglycerin Salbutamol MDI Salbutamol Nebulized Sodium Bicarbonate Introduction 2 Halton ACP Peel ACP Simcoe ACP Toronto Level II Level III Intro Scope of Practice — ACP The checklists for Scope of Practice are for paramedic reference only and might not accurately reflect the current scope of practice within specific services. Procedures List Halton ACP Peel ACP Simcoe ACP 12 Lead Acquisition Cardioversion CPAP Cricothyrotomy (Needle) CVAD Access Electronic Control Device Probe Removal Intubation (Nasal) Intubation (Oral) IO Access Up to Age 12 IV Access All Ages Needle Decompression Neonatal Resuscitation Pacing Pediatric Defib at 2-4 J/kg STEMI Bypass to PCI Lab Specific to Geographical Area TOR (Termination of Resuscitation) Medical TOR (Termination of Resuscitation) Trauma PCP ACP Special Events Notes Stroke Validation via Patch Supraglottic Airway Toronto Level II Level III Introduction 3 Scope of Practice — PCP The checklists for Scope of Practice are for paramedic reference only and might not accurately reflect the current scope of practice within specific services. Drug List Beausoleil Muskoka RAMA Halton PCP PCP PCP PCP Acetaminophen ASA Dextrose Dimenhydrinate (Gravol) Diphenhydramine (Benadryl) Epinephrine 1:1,000 Toronto Peel Simcoe PCP PCP Level I Level II Glucagon Ibuprofen Ketorolac (Toradol) Nitroglycerin Salbutamol MDI Salbutamol Nebulized Introduction 4 Intro Scope of Practice — PCP The checklists for Scope of Practice are for paramedic reference only and might not accurately reflect the current scope of practice within specific services. 12 Lead Acquisition CPAP Electronic Control Device Probe Removal Toronto Level I Level II IV Access All Ages IV Autonomous Neonatal Resuscitation Pediatric Defib at adult settings Pediatric Defib at 2-4 J/kg PCP Beausoleil Muskoka RAMA Halton Peel Simcoe PCP PCP PCP PCP PCP PCP STEMI Bypass to PCI lab specific to geographical area Stroke Validation via Patch TOR (Termination of Resuscitation) Medical TOR (Termination of Resuscitation) Trauma Notes Special Events Supraglottic Airway ACP Procedures List Introduction 5 Base Hospital Physicians On-Call Physicians Dr. Dr. Dr. Dr. Dr. Sanjay Michael Paul George Frank Agarwal Feldman Hoogeveen Karasmanis Martino Dr. Dr. Dr. Dr. Sheldon Jeff Oscar David Cheskes Handler Karbi Kazdan Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Valeria Jacques Deborah Carrie Andrew Russell Laurie Kevin Petar Luis Dominick Rachel Bruce Kevin Michael Alexandra Angela Jeffery Aikta Richard Leah Krym Lee Leung McQuarrie McDonald MacDonald Mazurik Mudrik Novakovic Robles Shelton Sheps Sawadsky Skarratt Schull Stefan Stone Tyberg Verma Verbeek Watson Emergency Physicians (SHSC) Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Dr. Zuhair Clare Mary Ann Melanie David Martin Michael Tina Alfonso Ivy Jordan Ross Graham Jennifer N. Michael Mark Lynne Rishi Paul Nicole Alsharafi Atzema Badali Baimel Barbic Betz Brzozowski Bhandari Burga Cheng Chenkin Claybo Cleghorn Chu Farkhani Feldman Freedman Fulton Ghosh Hawkins Kester-Greene Introduction 6 Notes Special Events ACP PCP Intro Patch Form Introduction 7 Patch Process Patch Number 1-877-822-8594 Mandatory Entry EHS # & Truck # _______ _______ Physician Mon − Fri, 8 am − 8 pm On-call Physician Mon − Fri, 8 pm − 8 am, Sat & Sun Sunnybrook Physician Note If the on-call physician does not answer within 24 seconds, the call will be automatically transferred to Sunnybrook. Patch Failure 1. 2. 3. 4. Attempt maximum twice by cell Attempt through CACC If no cell coverage attempt a radio patch through CACC If unable to contact a physician please refer to your medical directives Contact Self-Report 1. If a procedure was completed out of protocol 2. If a patch failure was experienced Introduction 8 Intro Patch Process — Toronto Patch Number 416-636-9871 Patch Failure Attempt maximum twice by cell Attempt through CACC If no cell coverage attempt a radio patch through CACC If unable to contact a physician please refer to your medical directives PCP 1. 2. 3. 4. Contact Self-Report Notes Special Events ACP 1. If a procedure was completed out of protocol 2. If a patch failure was experienced Introduction 9 Self-Reports Rationale Self-reporting is an important part of Paramedic practice: it equates to professionalism by taking responsibility for one’s own practice and is a form of education through self-remediation. The Base Hospital strives to improve not only individual Paramedic performance but also system performance through the clinical audit, self-reports, case review, feedback and educational processes. All processes are linked in order to reach a common goal, to improve patient safety and outcomes. Content Self-reports may include, but are not limited to, medical directive variances, documentation omissions, patch failures or omissions, scene time delays, or any challenges a Paramedic may encounter while on a call. Process Self-reports shall be posted online from the link at www.prehospitalmedicine.ca or emailed to [email protected] to ensure they are received, documented and followed-up in a timely manner. Mandatory information in your self-report shall contain: 1. Paramedic Service 2. Paramedic Name 3. Paramedic EHS Number 4. Call Date 5. Run Number and Vehicle Number 6. Call Location 7. A Brief Description of the Occurrence Being Reported 8. Contact Information Note You can expect a confirmation receipt acknowledging your self-report has been received. Additionally, there will be some indication of its status: self-remediation evident and closed or whether it has been redirected to the service-specific Paramedic Practice Manager for further review. Any request for call-back will be done by your Paramedic Practice Manager. Introduction 10 Intro ACP Medical Directives ....................................... Section 3 ACP Section 2 Special Events Medical Directives Section 4 Special Events ........................................ Notes ............................................................................ Section 8 Notes PCP Medical Directives PCP Patient Care Standards Introduction ......... Section 1 .................. Intro PCP ACP Special Events PATIENT CARE STANDARDS INTRODUCTION Notes Information contained herein has been carefully compiled and is believed to be accurate at date of publication. Freedom from error, however, cannot be guaranteed. Patient Care Standards Introduction Introduction Table of Contents Acknowledgements ........................................................................................................................... 3 Levels of Paramedics ......................................................................................................................... 4 Purpose of Standards ........................................................................................................................ 4 Format of the Advanced Life Support Patient Care Standards ............................................... 5 Use of the Medical Directives by Paramedics ............................................................................ 5 Regional Base Hospital Compliance with CPSO Policy ............................................................. 5 General Structure of a Medical Directive .................................................................................... 6 ALS Patient Care Standards Paramedic Skill Set ........................................................................ 6 Consent to Treatment and Capacity Assessment ...................................................................... 7 Refusal of Treatment ......................................................................................................................... 8 Comprehensive Care ......................................................................................................................... 9 Intravenous Access and Therapy by Primary Care Paramedics ............................................. 9 Home Medical Technology and Novel Medications ............................................................... 10 Patching .............................................................................................................................................. 11 Incident Reporting ........................................................................................................................... 11 Controlled Substances .................................................................................................................... 12 Responsibility of Care ...................................................................................................................... 12 Research ............................................................................................................................................. 13 Conventions ....................................................................................................................................... 13 List of Abbreviations ........................................................................................................................ 15 Reference and Educational Notes ............................................................................................... 18 Patient Care Standards Introduction 2 Intro Acknowledgements The development of this edition of the Advanced Life Support Patient Care Standards is the result of a collaborative effort of a number of stakeholders including: Association of Paramedic Chiefs (OAPC) Ontario Base Hospital Group (OBHG) Ministry of Health and Long Term Care – Emergency Health Services Branch (MOHLTC EHSB) EHSB Provincial Medical Advisory Committee (MAC) PCP In particular, the Ministry would like to gratefully acknowledge the following members of the MAC and regional base hospitals who provided the medical input into these standards: Dr. Jason Prpic, Chair Dr. Michael Lewell, Vice Chair Dr. Andrew Affleck Mr. Andy Benson Dr. Adam Dukelow Dr. Derek Garniss Mr. Kyle Grant Dr. Justin Maloney ACP Education Subcommittee Advanced Care Paramedic Representative Ms. Amie Maurice Mr. Paul Myre Primary Care Paramedic Representative Chair, Education Subcommittee Ms. Mary Osinga Dr. Bruce Sawadsky Dr. Ruby Vandersluis Special Events College Representative Dr. Richard Verbeek Notes Dr. Michelle Welsford Patient Care Standards Introduction 3 Levels of Paramedics In Ontario, there are three occupational levels of Paramedics: Primary Care Paramedic (PCP), Advanced Care Paramedic (ACP), and Critical Care Paramedic (CCP). A level of Paramedic is specified in Ontario Regulation 257/00 made under the Ambulance Act, RSO 1990, cA-19. Schedules 1, 2 and 3 in this regulation specify the mandatory controlled acts for each level of Paramedic. A Paramedic may be authorized by a medical director of a Regional Base Hospital (RBH) to perform controlled acts from the Schedule immediately above their prime occupational level. In this circumstance, the Paramedic will perform the skill to the specific standard set for the skill. This general concept also applies to the performance of controlled and non-controlled acts that are not included in Schedules 1, 2 and 3 but are specified in these standards. Purpose of Standards The purpose of the Advanced Life Support Patient Care Standards (ALS PCS) is to guide the specifics of patient care that are to be undertaken consistent with the scope of practice of the three occupational levels of Paramedics. The ALS PCS will: ▪ Reflect current practices for Paramedics in Ontario and provide a benchmark for Paramedic performance. ▪ Communicate to Paramedics, patients, other disciplines and the public in general, standards of practice and care by Paramedics in Ontario. ▪ Delineate Paramedic professional responsibilities and accountabilities. ▪ Provide a basis for evaluation of the patient care practice by Ontario’s Paramedics. ▪ Recognize that the scope of practice for each occupational level of Paramedic may have incremental add-ons with appropriate rationale and accountability. Summary ALS PCS for the three occupational levels of Paramedics in Ontario establish the practice and patient care parameters needed to provide high quality patient care in the varied settings throughout the province. The standards are designed to be dynamic to allow for changes based upon new medical evidence and/or standards of medical practice. Patient Care Standards Introduction 4 Intro Format of the Advanced Life Support Patient Care Standards This document is comprised of an Introduction section and six (6) appendices: PCP Appendix 1 – PCP Medical Directives Appendix 2 – ACP Medical Directives Appendix 3 – PCP Auxiliary Medical Directives Appendix 4 – ACP Auxiliary Medical Directives Appendix 5 – Chemical Exposure Medical Directives Appendix 6 – Maintenance of Certification Policy Critical Care Paramedics and Advanced/Primary Care Flight Paramedics will act in the provision of controlled acts in accordance with their base hospital medical directives under Ornge. Use of the Medical Directives by Paramedics ACP These medical directives apply to Paramedics who provide care under the license and/or authority of the RBH Medical Director. Delegation of controlled acts or medical directives in the ALS PCS to Paramedics falls under the exclusive oversight of the MOHLTC’s RBH Programs. Special Events The medical directives are designed to guide a Paramedic in the provision of timely and appropriate care to ill and injured patients in the prehospital setting, in accordance with the Paramedics training and authorized skill set. While great care has been taken in developing these medical directives, they cannot account for every clinical situation. Thus, they are not a substitute for sound clinical judgment. Regional Base Hospital Compliance with CPSO Policy Notes As licensed physicians in the Province of Ontario, the RBH Medical Directors must comply with the policies of the College of Physicians and Surgeons of Ontario (CPSO). CPSO policy #4-03, as may be amended from time to time, provides direction to Ontario physicians on the delegation of controlled acts, regardless of practice setting or type. RBHs will also follow a parallel process for delegation of non-controlled acts included in these Standards. Patient Care Standards Introduction 5 General Structure of a Medical Directive All medical directives follow the same format and are comprised of the following sections: Indication: The general medical complaint or problem to which the medical directive applies. Conditions: Clinical parameters that must be present for a procedure to be performed or for a drug to be administered. Contraindications: Clinical parameters that if present, preclude the performance of a procedure or the administration of a drug. Treatment: Description of the type of procedure to be performed or the dosing of a drug. Clinical Considerations: Key clinical points that provide general guidance to the proper performance of a procedure or the administration of a drug. All of these sections must be taken into account before and during the implementation of a medical directive. ALS Patient Care Standards Paramedic Skill Set The mandatory skill set for each level of Paramedic is derived from the controlled acts outlined in Schedules 1, 2, and 3 (as described above) and is implemented through the PCP and ACP Medical Directives. A Paramedic must meet all requirements within Regulation 257/00 to receive delegation from a RBH medical director. Additional (“Auxiliary”) skills may be delegated though use of the Auxiliary Medical Directives. Delegation of Auxiliary Medical Directives by a RBH medical director to Paramedics is optional and may be introduced after consultation and mutual agreement between the RBH and the certified ambulance service operator. Some PCP and ACP Medical Directives contain the phrase, “(if available)”. This phrase qualifies the skill or procedure as optional (i.e. auxiliary) even if included in PCP or ACP Medical Directives. Patient Care Standards Introduction 6 Intro Consent to Treatment & Capacity Assessment Except in emergency circumstances described below, paramedics must obtain the patient’s consent prior to initiating treatment. Consent may be informed or implied. Informed consent may be either verbal or written. Implied consent may be assumed where a person provides a physical indication that they consent to the treatment. For example, a patient who cannot speak but extends his hand to a paramedic after the paramedic indicates she is going to perform a simple procedure, such as a blood glucose determination may be giving implied consent to the procedure. PCP The elements required for consent to treatment are: ▪ consent must be given by a person who is capable of giving consent with respect to treatment, ▪ consent must relate to the treatment, ▪ consent must be informed, ▪ consent must be given voluntarily, and ▪ consent must not be obtained through misrepresentation or fraud. Special Events ACP Consent to treatment is informed if, before it is given to the person, he or she has: ▪ received the following information that a reasonable person in the same circumstances would require in order to make a decision about the treatment: the nature of the treatment, the expected benefits of the treatment, the material risks of the treatment, the material side effects of the treatment, alternative courses of action, the likely consequences of not having the treatment; and ▪ received responses to his or her requests for additional information about those matters. Notes The paramedic who proposes a treatment to a person shall ensure that consent is obtained. Valid consent requires that a person has the capacity to provide consent. A person is presumed to have the capacity to provide consent with respect to treatment and a paramedic may rely on that presumption. However, a capacity assessment may be required if it is not reasonable in the circumstances to presume the person is capable of consenting to the treatment. Patient Care Standards Introduction 7 A patient is capable with respect to treatment if the patient is: ▪ Able to understand the information that is relevant to making a decision about the treatment or alternatives being proposed; and ▪ Able to appreciate the reasonably foreseeable consequences of a decision or lack of decision with respect to treatment. If a paramedic is aware or is made aware that the person has a prior capable wish with respect to treatment, they must respect that wish (for example, if the person does not wish to be resuscitated). If a person is incapable with respect to a treatment, consent may be given or refused on his or her behalf by a person who is authorized to do so under section 20 of the Health Care Consent Act, 1996. In some instances, a person may present in an emergency situation where the person for whom the treatment is proposed is apparently experiencing severe suffering or is at risk, if the treatment is not administered promptly, of sustaining serious bodily harm. A paramedic may administer treatment to a person without consent in an emergency situation, if there is no other authorized person available to give or refuse consent and, in the opinion of the paramedic: ▪ the person is not capable of giving a consent or refusal to treatment; and ▪ the delay required to obtain a consent or refusal on the person’s behalf will prolong the suffering that the person is apparently experiencing or will put the person at risk of sustaining serious bodily harm. Refusal of Treatment If a patient refuses treatment, either in whole or in part, a Paramedic must comply with Basic Life Support (BLS) Patient Care Standards, Section 1 Part I, Patient Refusal of Treatment and/or Transport. Patient Care Standards Introduction 8 Intro Comprehensive Care While initiating and continuing treatment prescribed by these medical directives, a Paramedic must ensure that the patient simultaneously receives care in accordance with BLS Patient Care Standards. PCP It is acknowledged that there may be circumstances and situations where complying with Advanced Life Support Patient Care Standards is not clinically justified, possible, or prudent (e.g. multiple crews on scene, trapped patient, extenuating circumstances, competing patient care priorities). When treatment deviates from the standards, a Paramedic must document the care provided including reasoning for deviating from the Patient Care Standards. Intravenous Access and Therapy by Primary Care Paramedics Two levels of certification of PCPs for IV cannulation and therapy are possible. ACP “PCP Assist IV” authorizes a PCP to cannulate a peripheral IV at the request and under the direct supervision of an ACP. The patient must require a peripheral IV in accordance with the indications listed in the Intravenous Access and Fluid Therapy Medical Directive – Auxiliary. The ACP will perform all IV therapy in accordance with the Intravenous Access and Fluid Administration Protocol once intravenous access is obtained. PCPs certified in PCP Assist IV are not authorized to administer IV therapy. Special Events “PCP Autonomous IV” authorizes a PCP to independently cannulate an IV according to the Intravenous Access and Fluid Therapy Medical Directive – Auxiliary. PCPs certified in PCP Autonomous IV are authorized to administer IV therapy according to applicable medical directives. Notes Certification at each level shall meet the requirements established by the provincial Medical Advisory Committee. Patient Care Standards Introduction 9 Home Medical Technology and Novel Medications As community care advances, new home medical technologies and novel medications are being introduced for home use by highly trained patients and caregivers. They are generally used by patients with complex medical histories who may require emergent interventions which are not described in or aligned with the BLS or ALS Patient Care Standards. A “home medical technology” is an external or internal mechanical device prescribed by a regulated health professional for the purpose of treating a medical condition. A “novel medication” is a self/caregiver administered medication prescribed by a regulated health professional that is required to treat patients with generally rare and unusually complex chronic medical conditions which are often end stage. The medication may be self/caregiver-administered by any route into any part of the body. These can be encountered unexpectedly by Paramedics without any prior knowledge that these technologies or medications are being used in the community. Paramedics may not be familiar with the use of these technologies or medications even though they may be required to provide care. In some cases, when Base Hospital Medical Directors are alerted to these unique devices, medications or care requirements, a unique local medical directive may be issued to guide specific care for these patients. Such directives should be followed until further consideration by the Medical Advisory Committee. A Paramedic may assume patients or caregivers have knowledge about the technology or medication if they say they were trained. A Paramedic should advise the patient or caregiver to follow any specific steps or to provide any advice about restarting/stopping the device or novel medication. A Paramedic must always assist a patient within the authorized Paramedic skill set. When care requirements are uncertain, but the patient is stable, transport the patient. If the patient is unstable, consider patching to the Base Hospital Physician. Alternatively consider contacting the responsible regulated health professional. A Paramedic may follow written advice provided by their Base Hospital Medical Directors even if this advice is outside the conditions and contraindications of the BLS and ALS patient care standards. Patient Care Standards Introduction 10 Intro Patching A Paramedic should patch to the Base Hospital: ▪ When a medical directive contains a mandatory provincial patch point; OR ▪ When a RBH introduces a mandatory BH patch point; OR ▪ For situations that fall outside of these medical directives where the Paramedic PCP believes the patient may benefit from online medical direction that falls within the prescribed Paramedic scope of practice; OR ▪ When there is uncertainty about the appropriateness of a medical directive, either If a BHP directs a Paramedic to perform an assessment or intervention that exceeds the Paramedic’s scope of practice, the Paramedic must advise the BHP of such and notify the physician that she/he cannot comply with the direction as it exceeds her/his scope of practice. In such cases, a Paramedic should ask the BHP to provide alternative direction. Incident Reporting Special Events In cases where a treatment option requires the prior authorization by the BHP (i.e. mandatory provincial patch point or mandatory BH patch point) AND the BHP cannot be reached despite reasonable attempts by the Paramedic to establish contact, a Paramedic may initiate the required treatment without the requisite online authorization if the patient is in severe distress and in the Paramedic’s opinion the medical directive would otherwise apply. Clinical judgment must be applied and an acceptable standard of care must be met. This may be based on peer and expert review. In such cases, a Paramedic should continue attempts to contact the BHP after the treatment has been initiated. All patch failures must be reported in a timely manner in accordance with local policy and procedures. Paramedics should document the attempts to patch to the BH on their call report. ACP in whole or in part. Notes Paramedics shall adhere to the Service Operator Policies and MOHLTC Ambulance Service Documentation Standards for incident reporting. Paramedics shall also adhere to additional RBH policies regarding reporting of clinical care incidents to the RBH. Patient Care Standards Introduction 11 Controlled Substances Where applicable, Paramedics and Ambulance Service Operators shall comply with the Canada Controlled Drug and Substances Act, SC 1996, c 19 and its Regulations, in accordance with the ambulance operator and RBH policy. This shall include that controlled substances (opiates and benzodiazepines) are stored in different carrying cases than other medications. Responsibility of Care While on scene, the highest level Paramedic shall assess the patient and make a decision on the level of care required and the level of Paramedic responsible for the patient. The highest level Paramedic is the ultimate patient care authority on the scene. If there is any disagreement between Paramedics, the Base Hospital physician may be contacted. It is expected that when an intervention has been performed, the Paramedic most appropriate for that intervention will remain responsible for the patient. In all patient care, the highest level of Paramedic is responsible for the care of the patient, including decisions on the level of care required during transport. A Paramedic may choose to assign aspects of care and procedures to an alternate level Paramedic as long as the procedure is within that Paramedic’s scope of practice. Paramedics must alert the highest level Paramedic of any change of patient status. When transferring care from one level of Paramedic to another, Paramedics shall provide: ▪ current CTAS level; ▪ a history of the patient’s current problem(s) and relevant past medical history; ▪ pertinent physical findings; ▪ a summary of management at scene/enroute; ▪ the patient’s response to treatment, including most recent vital signs; ▪ the reason for transfer in cases of inter-facility transfers. The transfer of responsibility of patient care is a critical juncture along the clinical care continuum. When transferring patient care to another health care provider (e.g. nurse, physician, etc.), a Paramedic must comply with BLS Patient Care Standards regarding such transfers. Patient Care Standards Introduction 12 PCP Clinical research is fundamental to the practice of medicine and the development of safer, more effective treatment options for patients. At times research protocols require temporary changes to patient care standards. In recognition of the importance of prehospital clinical research, RBH Medical Directors may delegate changes in patient care standards to Paramedics if the research-related treatment is endorsed by MAC– OBHG and the certified ambulance operator, approved by MOHLTC and is supported by an appropriate research ethics review board. Changes to patient care standards will be introduced as an auxiliary medical directive. Upon completion of a prehospital clinical trial, research-related treatment must be halted and care as prescribed by BLS and ALS Patient Care Standards must resume. Intro Research conventions The word ‘consider’ is used repeatedly throughout the medical directives. Where this word appears, it indicates that a Paramedic should initiate the treatment unless there is strong clinical rationale to withhold it. A Paramedic must document his/her justification for withholding treatment on the call report. ACP “Conventions” refers to a consistent application of terms throughout the medical directives based on definitions below. Drug doses may be either in per kilogram or fixed doses depending on common clinical practice. The number of recommended drugs doses may be administered regardless of any previous self-administration by a patient. When more than one route of drug administration is listed, the order of preference for route of administration is from left to right. Clinical circumstances for each case should determine the final route chosen. Notes Pediatric drug doses can vary slightly according to the source of expert opinion. The pediatric drug doses in the ALS PCS are the preferred doses. However, drug doses as determined by an up-to-date version of a widely accepted pediatric emergency tape (e.g. Broselow Tape) is an acceptable alternative. Use of a pediatric emergency tape shall be documented on the patient care report when it is used to determine a pediatric drug dose. Special Events Drug Doses and Administration Patient Care Standards Introduction 13 Age and Vital Signs The general age cut off between adults and pediatrics is 18 years. There is a wide range of “normal” for vital signs in adults and especially pediatrics. As much as possible, ages for pediatrics and cut off points for vital signs have been kept consistent throughout the medical directives. However, clinical research and expert opinion have resulted in a number of exceptions which in each case has been deliberately chosen and is clearly noted in each medical directive. There is a deliberate gap in the definition of normotension and hypotension in adults. Adults Normotension: Hypotension: Heart Rate: Bradycardia: Tachycardia: Tachypnea: SBP ≥ 100mmHg SBP < 90 mmHg Heart rate is always in beats per minute according to a cardiac monitor when it is applied. In situations where a cardiac monitor is not indicated then the heart rate is equal to the pulse rate. < 50 BPM ≥ 100 BPM RR ≥ 28 breath/min Pediatrics Age 0 − 3 months 3 − 6 months 6 − 12 months 1 − 3 yr 6 yr 10 yr Respiratory Rate 30 − 60 30 − 60 25 − 45 20 − 30 16 − 24 14 − 20 Heart Rate 90 − 180 80 − 160 80 − 140 75 − 130 70 − 110 60 − 90 Systolic Blood Pressure (for children 1-10 yrs) = 70 + (2 x age in years) Weight (kg) = (age x 2) + 10 Hypoglycemia Age ≥ 2 years: glucometry < 4.0 mmol/L Age < 2 years: glucometry < 3.0 mmol/L LOA (Level of Awareness) ▪ The word ‘altered’ refers to a GCS that is less than normal for the patient. ▪ The word ‘unaltered’ refers to a GCS that is normal for the patient. This may be a GCS < 15. Patient Care Standards Introduction 14 Intro List of Abbreviations The following abbreviations, in alphabetical order, appear in the ALS Patient Care Standards: A Advanced Care Paramedic Advanced Life Support Advanced Life Support Patient Care Standards acetylsalicylic acid atrioventricular PCP ACP ALS ALS PCS ASA AV B BH BHP BLS BP BPM BVM base hospital Base Hospital Physician Basic Life Support blood pressure beats per minute bag-valve-mask C ACP Critical Care Paramedic chronic obstructive pulmonary disease centimeter continuous positive airway pressure Cardiopulmonary Resuscitation College of Physicians and Surgeons of Ontario Canadian Triage and Acuity Scale cerebral vascular accident central venous access device Special Events CCP COPD cm CPAP CPR CPSO CTAS CVA CVAD D DKA diabetic ketoacidosis E electronic control device electrocardiogram esophageal detection device end tidal carbon dioxide endotracheal tube Notes ECD ECG EDD ETCO2 ETT Patient Care Standards Introduction 15 F FiO2 FRI fraction of inspired oxygen febrile respiratory infection G g GCS gram Glasgow Coma Scale H H 2O HR Hx water heart rate history I IM IN IO IV intramuscular intranasal intraosseous intravenous K kg kilogram L LOA LOC level of awareness level of consciousness/loss of consciousness M MAC mcg MDI mg min ml/kg mmHg MOHLTC Medical Advisory Committee microgram metered dose inhaler milligram minute milliliter per kilogram millimeters of mercury Ministry of Health and Long-Term Care N N/A NaCl nare NEB NPA NSAID not applicable sodium chloride nostril nebulized nasopharyngeal airway non-steroidal anti-inflammatory drug Patient Care Standards Introduction 16 O Ontario Base Hospital Group oropharyngeal airway Intro OBHG OPA P PCP PO PRN Primary Care Paramedic by mouth/oral as needed Q every PCP q R RBH ROSC RR Regional Base Hospital return of spontaneous circulation respiratory rate S subcutaneous sublingual systolic blood pressure saturation of peripheral oxygen ST-segment elevation myocardial infarction ACP SC SL SBP SpO2 STEMI T traumatic brain injury tricyclic antidepressant transcutaneous pacing Special Events TBI TCA TCP U URTI upper respiratory tract infection V VSA vital signs absent W within normal limits Notes WNL Patient Care Standards Introduction 17 Reference and Educational Notes The RBHs have created a companion document of reference and educational notes intended to assist paramedics in implementing these medical directives. This will facilitate regular updating of these notes without having to issue frequent changes to the standards. It is expected that paramedics have mastered the relevant information as part of initial training and certification and have maintained their knowledge through continuing education and self-study. The reference and educational notes do not define a standard of care; however, they should be considered useful in ensuring that an appropriate standard of care is met. To access these documents, type the following address into a web browser: http://www.ontariobasehospitalgroup.ca/educational-resources/Default.aspx Or, if viewing this document digitally, follow this link: Ontario Base Hospital Group Educational Resources Patient Care Standards Introduction 18 Intro PCP ACP Notes Special Events PCP MEDICAL DIRECTIVES PCP Medical Directives PCP Medical Directives Table of Contents PCP Core Medical Directives Medical Cardiac Arrest Medical Directive .............................................................................. 3 Trauma Cardiac Arrest Medical Directive .............................................................................. 6 Hypothermia Cardiac Arrest Medical Directive ................................................................... 10 Foreign Body Airway Obstruction Cardiac Arrest Medical Directive ............................ 12 Neonatal Resuscitation Medical Directive ........................................................................... 14 Return of Spontaneous Circulation (ROSC) Medical Directive ....................................... 16 Cardiac Ischemia Medical Directive ....................................................................................... 18 Acute Cardiogenic Pulmonary Edema Medical Directive ................................................. 20 Cardiogenic Shock Medical Directive .................................................................................... 22 Hypoglycemia Medical Directive ............................................................................................ 23 Bronchoconstriction Medical Directive ................................................................................ 25 Moderate to Severe Allergic Reaction Medical Directive ................................................ 28 Croup Medical Directive ........................................................................................................... 30 PCP Auxiliary Medical Directives Intravenous and Fluid Therapy Medical Directive – AUXILIARY ....................................... 32 Continuous Positive Airway Pressure (CPAP) Medical Directive – AUXILIARY .............. 34 Supraglottic Airway Medical Directive – AUXILIARY ............................................................ 36 Nausea/Vomiting Medical Directive – AUXILIARY ................................................................ 38 Electronic Control Device Probe Removal Medical Directive – AUXILIARY ................... 40 Analgesia Medical Directive – AUXILIARY ............................................................................... 41 Moderate to Severe Pain Medical Directive – AUXILIARY ................................................ 43 Blank pages left for future Medical Directives ......................................................................... 45 PCP Medical Directives 2 Intro Medical Cardiac Arrest Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized Indications Non-traumatic cardiac arrest Conditions AGE: N/A AGE: ≥30 days AGE: ≥30 days LOA: LOA: Altered LOA: Altered N/A HR: N/A HR: N/A HR: RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: Shock indicated Epinephrine Other: VF or pulseless VT Medical TOR AGE: N/A AGE: ≥18 years LOA: Altered LOA: Altered HR: N/A HR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A Other: Arrest not witnessed by EMS, AND No ROSC AND No shocks delivered Notes Other: Anaphylaxis suspected as causative event ACP Other: Performed for 2 minute intervals Special Events Altered PCP Manual Defibrillation AED Defibrillation CPR PCP Medical Directives 3 Contraindications CPR Obviously dead as per BLS standards AED Defibrillation Non-shockable rhythm Manual Defibrillation Rhythms other than VF or pulseless VT Meet conditions of DNR standard Medical TOR Epinephrine Arrest thought to be of non-cardiac origin Allergy or sensitivity to epinephrine Treatment Consider CPR Consider AED defibrillation (with pediatric attenuator if available): Dose Max. single dose Dosing interval Max. # of doses Age ≥30 days to <8 years With Ped Without Ped attenuator attenuator 1 shock 1 shock As per BH / As per BH / manufacturer manufacturer N/A N/A 4 4 Age ≥8 years 1 shock As per BH / manufacturer N/A 4 Consider Manual defibrillation (if certified and authorized): Dose First dose Subsequent and max. dose(s) Dosing interval Max. # of doses Age Age ≥30 days to <8 years ≥8 years 1 shock 1 shock 2 J/kg As per BH / manufacturer 4 J/kg As per BH / manufacturer 2 min 2 min 4 4 PCP Medical Directives 4 Weight N/A Route IM Concentration 1:1,000 0.01 mg/kg* 0.5 mg N/A 1 PCP Dose Max. single dose Dosing interval Max. # of doses Intro Consider epinephrine (only if anaphylaxis suspected as causative event): * The epinephrine dose may be rounded to the nearest 0.05 mg. MANDATORY PROVINCIAL PATCH POINT: ACP Patch to BHP for authorization, following the 3rd analysis, to consider Medical Termination of Resuscitation (TOR) (if applicable). If the BH patch fails, or the medical TOR does not apply, transport to the closest appropriate receiving hospital following ROSC or the 4th analysis. Clinical Considerations In unusual circumstances (e.g.: pediatric patients or toxicological overdoses), consider initiating transportation following the first rhythm analysis that does not result in a defibrillation being delivered. Special Events A Paramedic may choose to move the patient to the ambulance prior to initiating the TOR if family is not coping well or the arrest occurred in a public place. Notes Follow the Deceased Patient Standard once TOR has been implemented. PCP Medical Directives 5 Trauma Cardiac Arrest Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized Indications Cardiac arrest secondary to severe blunt or penetrating trauma Conditions CPR AED Defibrillation Manual Defibrillation AGE: N/A AGE: ≥30 days AGE: ≥30 days LOA: Altered LOA: Altered LOA: Altered HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: N/A Other: Shock indicated Other: VF or pulseless VT Trauma TOR AGE: ≥16 years LOA: Altered HR: 0 RR: 0 SBP: N/A Other: No palpable pulses No defibrillation delivered and monitored HR = 0 (asystole) OR monitored HR >0 AND the closest ER ≥30 min transport time away. PCP Medical Directives 6 CPR AED Defibrillation Obviously dead as per BLS standards Non-shockable rhythm Intro Contraindications Manual Defibrillation Rhythms other than VF or pulseless VT Meet conditions of DNR standard Trauma TOR PCP Age <16 years Shock delivered Monitored HR >0 and closest ER <30 min away Treatment Consider CPR 1 shock As per BH / manufacturer N/A 1 Special Events Dosing interval Max. # of doses Age ≥8 years Notes Dose Max. single dose Age ≥30 days to <8 years With Ped Without Ped attenuator attenuator 1 shock 1 shock As per BH / As per BH / manufacturer manufacturer N/A N/A 1 1 ACP Consider AED defibrillation: PCP Medical Directives 7 Consider Manual defibrillation (if certified and authorized): Dose Age ≥30 days to <8 years 1 shock Initial dose 2 J/kg Dosing interval Max. # of doses N/A 1 Age ≥8 years 1 shock As per BH / manufacturer N/A 1 MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to apply the Trauma (TOR) Termination of Resuscitation, if applicable. If the BH patch fails, or the trauma TOR does not apply, transport to the closest appropriate receiving hospital following the first analysis/ shock. Clinical Considerations If no obvious external signs of significant blunt trauma, consider medical cardiac arrest and treat according to the appropriate medical cardiac arrest directive. PCP Medical Directives 8 Intro Treatment – Algorithm for Trauma Arrest INDICATIONS: Cardiac arrest secondary to severe blunt or penetrating trauma CPR (throughout duration of call) PCP Apply defib pads to all patient ≥30 days of age – Rhythm analysis YES PEA (HR >0) Asystole YES YES NO Pt age ≥16 yrs YES YES Drive time to closest ER >30 min ACP Defibrillation: 1 shock, Max # doses = 1 YES Transport to Emergency Department YES Other monitored rhythm NO Special Events VF or VT YES NO Patch YES NO TOR implemented Notes Transport to ED PCP Medical Directives 9 Hypothermia Cardiac Arrest Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Cardiac arrest secondary to severe hypothermia Conditions AED Defibrillation CPR Manual Defibrillation AGE: N/A AGE: ≥30 days AGE: ≥30 days LOA: Altered LOA: Altered LOA: Altered HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A N/A SBP: N/A SBP: N/A SBP: Other: N/A Other: Shock indicated Other: VF or pulseless VT Contraindications CPR Obviously dead as per BLS standards AED Defibrillation Non-shockable rhythm Meet conditions of DNR standard Treatment Consider CPR PCP Medical Directives 10 Manual Defibrillation Rhythms other than VF or pulseless VT Max. single dose Dosing interval Max. # of doses Age ≥8 years 1 shock As per BH / manufacturer N/A 1 PCP Dose Age ≥30 days to <8 years With Ped Without Ped attenuator attenuator 1 shock 1 shock As per BH / As per BH / manufacturer manufacturer N/A N/A 1 1 Intro Consider AED defibrillation (with pediatric attenuator if available): Consider Manual defibrillation: Initial dose Dosing interval Max. # of doses 2 J/kg N/A 1 Age ≥8 years 1 shock As per BH / manufacturer N/A 1 ACP Dose Age ≥30 days to <8 years 1 shock Transport to the closest appropriate facility without delay following the first analysis. Special Events Clinical Considerations Notes N/A PCP Medical Directives 11 Foreign Body Airway Obstruction Cardiac Arrest Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Cardiac arrest secondary to an airway obstruction Conditions CPR AED Defibrillation Manual Defibrillation AGE: N/A AGE: ≥30 days AGE: ≥30 days LOA: Altered LOA: Altered LOA: Altered HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: N/A Other: Shock indicated Other: VF or pulseless VT Contraindications CPR Obviously dead as per BLS standards AED Defibrillation Non-shockable rhythm Meet conditions of DNR standard Treatment Consider CPR Consider foreign body removal: (utilizing BLS maneuvers) PCP Medical Directives 12 Manual Defibrillation Rhythms other than VF or pulseless VT Max. single dose Dosing interval Max. # of doses N/A 1 N/A 1 Age ≥8 years 1 shock As per BH / manufacturer N/A 1 PCP Dose Age ≥30 days to <8 years With Ped Without Ped attenuator attenuator 1 shock 1 shock As per BH / As per BH / manufacturer manufacturer Intro Consider AED defibrillation (with pediatric attenuator if available): Consider Manual defibrillation: Age ≥8 years 1 shock As per BH / manufacturer N/A 1 ACP Dose Initial dose Dosing interval Max. # of doses Age ≥30 days to <8 years 1 shock 2 J/kg N/A 1 If the patient is in cardiac arrest following removal of the obstruction, initiate management as a medical cardiac arrest. Special Events If the obstruction cannot be removed, transport to the closest appropriate facility without delay following the first analysis. Clinical Considerations Notes N/A PCP Medical Directives 13 Neonatal Resuscitation Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Severe cardio-respiratory distress Conditions Resuscitation AGE: Newborn or <30 days of age LOA: N/A HR: N/A RR: N/A SBP: N/A Other: Less than full term, or meconium, or poor APGAR score Contraindications Resuscitation Clear of meconium Breathing or crying Good muscle tone Pink in colour PCP Medical Directives 14 Birth: Intro Treatment Routine Care: Clear of *meconium? Breathing or crying? Good muscle tone? Colour pink? Term gestation YES Provide warmth Clear airway if necessary Do not routinely suction Dry Ongoing evaluation PCP NO Provide warmth Position/clear airway (as necessary) Dry, stimulate, reposition Evaluate respirations, heart rate and colour Breathing Supportive care ACP 30 Sec HR ≥100 + pink Apnea, gasping or HR <100 Provide positive pressure ventilation (BVM) using air HR <60 90 Sec Ventilating Supportive care HR ≥100 + pink HR ≥60 Special Events 60 Sec Provide positive pressure ventilation (BVM/ETT) using 100% oxygen Administer chest compressions Initiate transport Notes *if meconium is present and baby not vigorous, suction mouth and pharynx and provide BVM ventilations as required and then continue with the remainder of the initial steps following birth. PCP Medical Directives 15 Return of Spontaneous Circulation (ROSC) Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Patient with return of spontaneous circulation (ROSC) after the resuscitation was initiated. Conditions 0.9% NaCl fluid bolus AGE: N/A Therapeutic hypothermia AGE: males ≥18 years LOA: N/A HR: N/A LOA: Altered RR: N/A HR: N/A SBP: Hypotension RR: N/A SBP: ≥90 mmHg (spontaneous or following bolus administered) Other: Chest auscultation is clear females ≥50 years Other: N/A Contraindications Therapeutic hypothermia 0.9% NaCl fluid bolus Fluid overload SBP ≥90 mmHg Traumatic cardiac arrest (blunt, penetrating or burn) Sepsis or serious infection suspected as cause of arrest Hypothermic arrest Known coagulopathy (medical history or medications) PCP Medical Directives 16 Intro Treatment Consider rapid transport Consider optimizing ventilation and oxygenation: Titrate oxygenation ≥94% Avoid hyperventilation and target an ETCO2 of 35–40 mmHg with continuous waveform capnography (if available) Infusion Infusion interval Reassess every Age ≥12 years Route IV 10 ml/kg Immediate 250 ml 1,000 ml 1,000 ml ACP Max. volume Age <12 years Route IV 10 ml/kg Immediate 100 ml PCP Consider 0.9% NaCl fluid bolus (if certified and authorized): Consider 12 lead acquisition (if available) Consider Therapeutic hypothermia (if available) Special Events Clinical Considerations Notes The application of therapeutic hypothermia should not detract from rapid transport, optimizing ventilation and oxygenation or the management of a re-arrest. PCP Medical Directives 17 Cardiac Ischemia Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Suspected cardiac ischemia Conditions ASA Nitroglycerin AGE: ≥18 years AGE: ≥18 years LOA: Unaltered LOA: Unaltered HR: N/A HR: 60–159 bpm RR: N/A RR: N/A SBP: N/A SBP: Normotension Other: Able to chew and swallow Other: Prior history of nitroglycerin use OR IV access obtained Contraindications ASA Allergy or sensitivity to ASA or NSAIDS If asthmatic, no prior use of ASA Current active bleeding CVA or TBI in the previous 24 hours Nitroglycerin Allergy or sensitivity to nitrates Phosphodiesterase inhibitor use within the previous 48 hours SBP drops by one-third or more of its initial value after nitroglycerin is administered 12-lead ECG compatible with right ventricular infarct PCP Medical Directives 18 Intro Treatment Consider ASA: Dose Max. single dose Dosing interval Max. # of doses PCP Route PO 160–162 mg 162 mg N/A 1 Consider 12-lead ECG acquisition (if available) Consider nitroglycerin: Max. single dose Dosing interval Max. # of doses 0.4 mg 5 min. 6 ACP Dose SBP ≥100 mmHg Route SL 0.3 or 0.4 mg Clinical Considerations Notes Special Events N/A PCP Medical Directives 19 Acute Cardiogenic Pulmonary Edema Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Moderate to severe respiratory distress AND Suspected acute cardiogenic pulmonary edema Conditions Nitroglycerin AGE: ≥18 years LOA: N/A HR: 60–159 bpm RR: N/A SBP: Normotension Other: Ascertain prior history of nitroglycerin use OR establish IV access Contraindications Nitroglycerin Allergy or sensitivity to nitrates Phosphodiesterase inhibitor use within the previous 48 hours SBP drops by one-third or more of its initial value after nitroglycerin is administered PCP Medical Directives 20 Intro Treatment Consider nitroglycerin: NOTE: SBP ≥140 mmHg IV or Hx No Route SL 0.3 or 0.4 mg 0.4 mg 5 min. 6 IV or Hx Yes Route SL 0.6 or 0.8 mg 0.8 mg 5 min. 6 PCP Dose Max. single dose Dosing interval Max. # of doses SBP 100 mmHg to <140 mmHg IV or Hx Yes Route SL 0.3 or 0.4 mg 0.4 mg 5 min. 6 Hx refers to a patient with a prior history of nitroglycerin use. ACP Consider 12-lead ECG acquisition (if available) Clinical Considerations Notes Special Events IV condition applies only to PCPs certified to the level of PCP Autonomous IV. PCP Medical Directives 21 Cardiogenic Shock Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications STEMI-positive ECG AND cardiogenic shock Conditions 0.9% NaCl AGE: ≥2 years LOA: N/A HR: N/A RR: N/A SBP: Hypotension Other: Clear chest on auscultation Contraindications 0.9% NaCl N/A Treatment Consider 0.9% NaCl fluid bolus: Infusion Infusion interval Reassess every Max. volume Age ≥2 years to <18 years Route IV 10 ml/kg N/A 100 ml 10 ml/kg Clinical Considerations N/A PCP Medical Directives 22 Age ≥18 years Route IV 10 ml/kg N/A 250 ml 10 ml/kg A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Intro Hypoglycemia Medical Directive Indications Agitation OR altered LOA OR seizure OR symptoms of stroke Conditions Dextrose AGE: ≥2 years AGE: N/A LOA: Altered LOA: Altered HR: N/A HR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A Other: Hypoglycemia ACP Other: Hypoglycemia PCP Glucagon Contraindications Dextrose Allergy or sensitivity to dextrose Glucagon Allergy or sensitivity to glucagon Special Events Pheochromocytoma Treatment Notes Perform glucometry PCP Medical Directives 23 Consider dextrose (if certified and authorized) or glucagon: Dose Max. single dose Dosing interval Max. # of doses Drug Dextrose Age ≥2 years Weight N/A Concentration D50W Route IV 0.5 g/kg (1 ml/kg) 25 g (50 ml) 10 min. 2 Drug Glucagon Age N/A Weight <25 kg Concentration N/A Route IM 0.5 mg 0.5 mg 20 min. 2 Weight ≥25 kg Concentration N/A Route IM 1 mg 1 mg 20 min. 2 Clinical Considerations If the patient responds to dextrose or glucagon, he/she may receive oral glucose or other simple carbohydrates. If only mild signs or symptoms are exhibited, the patient may receive oral glucose or other simple carbohydrates instead of dextrose or glucagon. If a patient initiates an informed refusal of transport, a final set of vital signs including blood glucometry must be attempted and documented. IV administration of dextrose applies only to PCPs certified to the level of PCP Autonomous IV. PCP Medical Directives 24 A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Intro Bronchoconstriction Medical Directive Indications Respiratory distress AND Suspected bronchoconstriction Epinephrine Epinephrine Autoinjector AGE: N/A AGE: LOA: N/A WEIGHT: N/A WEIGHT: ≥10 kg HR: N/A LOA: N/A LOA: N/A RR: N/A HR: N/A HR: N/A SBP: N/A RR: BVM ventilation required RR: BVM ventilation required SBP: N/A SBP: N/A Other: Hx of asthma Other: Hx of asthma Other: N/A AGE: N/A N/A ACP Salbutamol PCP Conditions Contraindications Allergy or sensitivity to epinephrine Epinephrine Autoinjector Special Events Allergy or sensitivity to salbutamol Epinephrine Allergy or sensitivity to epinephrine Notes Salbutamol PCP Medical Directives 25 Treatment Consider salbutamol: Weight <25 kg Dose Max. Single Dose Dosing interval Max. # of doses Route MDI* (if available) Up to 600 mcg (6 puffs) 600 mcg 5–15 min. PRN 3 Weight ≥25 kg Route NEB 2.5 mg 2.5 mg 5–15 min. PRN 3 Route MDI* (if available) Up to 800 mcg (8 puffs) 800 mcg 5–15 min. PRN 3 Route NEB 5 mg 5 mg 5–15 min. PRN 3 * 1 puff=100mcg Consider epinephrine: Weight N/A Route IM Concentration 1:1,000 Dose 0.01 mg/kg** Max. single dose Dosing interval Max. # of doses 0.5 mg N/A 1 Weight ≥10 kg to <25 kg Route Pediatric Autoinjector Concentration 1:1,000 1 injection (0.15 mg) 1 injection N/A 1 Weight ≥25 kg Route Adult Autoinjector Concentration 1:1,000 1 injection (0.3 mg) 1 injection N/A 1 ** The epinephrine dose may be rounded to the nearest 0.05 mg. PCP Medical Directives 26 Intro Clinical Considerations Epinephrine should be the first drug administered if the patient is apneic. Salbutamol MDI may be administered subsequently using a BVM MDI adapter (if available). Nebulization is contraindicated in patients with a known or suspected fever or in the setting of a declared febrile respiratory illness outbreak by the local medical officer of health. When administering salbutamol MDI, the rate of administration should be 100 mcg approximately every 4 breaths. PCP A spacer should be used when administering salbutamol MDI (if available). MANDATORY PROVINCIAL PATCH POINT: Notes Special Events ACP Patch to BHP for authorization to use pediatric autoinjector for patients <10 kg. PCP Medical Directives 27 Moderate to Severe Allergic Reaction Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Exposure to a probable allergen AND Signs and/or symptoms of a moderate to severe allergic reaction (including anaphylaxis) Conditions Epinephrine AGE: N/A Epinephrine Autoinjector AGE: N/A Diphenhydramine AGE: N/A WEIGHT: N/A WEIGHT: ≥10 kg WEIGHT: ≥25 kg LOA: LOA: N/A LOA: N/A N/A N/A HR: N/A HR: N/A HR: RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: For anaphylaxis only Other: For anaphylaxis only Other: N/A Contraindications Epinephrine Allergy or sensitivity to epinephrine Epinephrine Autoinjector Allergy or sensitivity to epinephrine PCP Medical Directives 28 Diphenhydramine Allergy or sensitivity to diphenhydramine Intro Treatment Consider epinephrine: IM Concentration 1:1,000 Dose 0.01 mg/kg* Max. single dose Dosing interval Max. # of doses 0.5 mg N/A 1 Weight ≥10 kg to <25 kg Route Pediatric Autoinjector Concentration 1:1,000 1 injection (0.15 mg) 1 injection N/A 1 Weight ≥25 kg Route Adult Autoinjector Concentration 1:1,000 1 injection (0.3 mg) 1 injection N/A 1 PCP Weight N/A Route *The epinephrine dose may be rounded to the nearest 0.05 mg. Consider diphenhydramine (if certified and authorized): Route IV 50 mg 50 mg N/A 1 ACP Weight ≥50 kg Route IM 50 mg 50 mg N/A 1 Clinical Considerations Epinephrine should be the first drug administered in anaphylaxis. IV administration of diphenhydramine applies only to PCPs certified to the level of PCP Autonomous IV. Special Events Dose Max. single dose Dosing interval Max. # of doses Weight ≥25 kg to <50 kg Route Route IV IM 25 mg 25 mg 25 mg 25 mg N/A N/A 1 1 MANDATORY PROVINCIAL PATCH POINT: Notes Patch to BHP for authorization to use pediatric autoinjector for patients <10 kg PCP Medical Directives 29 Croup Medical Directive A Primary Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Severe respiratory distress AND Stridor at rest AND Current history of URTI AND Barking cough OR recent history of a barking cough Conditions Epinephrine AGE: <8 years LOA: N/A HR: <200 bpm RR: N/A SBP: N/A Other: N/A Contraindications Epinephrine Allergy or sensitivity to epinephrine PCP Medical Directives 30 Intro Treatment Consider epinephrine: <1 year Dose Max. single dose Dosing interval Max. # of doses Weight <5 kg Route NEB Concentration 1:1,000 0.5 mg 0.5 mg N/A 1 Weight ≥5 kg Route NEB Concentration 1:1,000 2.5 mg 2.5 mg N/A 1 Age ≥1 year to 8 years Weight N/A Route NEB Concentration 1:1,000 5 mg 5 mg N/A 1 PCP Age Clinical Considerations Notes Special Events ACP The minimum initial volume for nebulization is 2.5 ml. PCP Medical Directives 31 Intravenous and Fluid Therapy Medical Directive – AUXILIARY A Primary Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized according to the PCP Autonomous IV level. Indications Actual or potential need for intravenous medication OR fluid therapy Conditions IV Fluid Bolus AGE: ≥2 years AGE: ≥2 years LOA: N/A LOA: N/A HR: N/A HR: N/A RR: N/A RR: N/A SBP: N/A SBP: Hypotension Other: N/A Other: N/A Contraindication Fluid Bolus IV Suspected fracture proximal to the access site. Signs of fluid overload Treatment Consider IV cannulation PCP Medical Directives 32 Age ≥12 years Route IV 30–60 ml/hr N/A N/A N/A PCP Infusion Infusion interval Reassess every Max. volume Age ≥2 years to <12 years Route IV 15 ml/hr N/A N/A N/A Intro Consider 0.9% NaCl maintenance infusion: MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to administer IV NaCl bolus to a patient ≥2 years to <12 years with suspected Diabetic Ketoacidosis (DKA) Consider 0.9% NaCl fluid bolus: Age ≥12 years Route IV 20 ml/kg Immediate 250 ml 2,000 ml ACP Infusion Infusion interval Reassess every Max. volume* Age ≥2 years to <12 years Route IV 20 ml/kg Immediate 100 ml 20 ml/kg up to 2,000 ml Clinical Considerations “PCP Assist IV” authorizes a PCP to cannulate a peripheral IV at the request and under the direct supervision of an ACP. The patient must require a peripheral IV in accordance with the indications listed in this Medical Directive. PCPs certified in PCP Assist IV are not authorized to administer IV fluid or medication therapy. Special Events *The maximum volume of NaCl is lower for patients in cardiogenic shock Notes Microdrips and or volume control administration sets should be considered when IV access is indicated for patients less than 12 years of age. PCP Medical Directives 33 Continuous Positive Airway Pressure (CPAP) Medical Directive – AUXILIARY A Primary Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Severe respiratory distress AND Signs and/or symptoms of acute pulmonary edema OR COPD Conditions CPAP AGE: ≥18 years LOA: N/A HR: N/A RR: Tachypnea SBP: Normotension Other: SpO2 <90% or accessory muscle use Contraindications CPAP Asthma exacerbation Suspected pneumothorax Unprotected or unstable airway Major trauma or burns to the head or torso Tracheostomy Inability to sit upright Unable to cooperate Hypotension PCP Medical Directives 34 Intro Treatment Consider CPAP: Initial setting Titration increment Titration interval 2.5 cm H2O Or equivalent flow rate of device as per BH direction Or equivalent flow rate of device as per BH direction 5 min. 15 cm H2O Or equivalent flow rate of device as per BH direction PCP Max. setting 5 cm H2O Consider increasing FiO2 (if available): 50–100% FiO2 increment (if available on device) SpO2 <92% despite treatment and/or 10cm H2O pressure or equivalent flow rate of device as per BH direction Max FiO2 100% ACP Initial FiO2 Confirm CPAP pressure by manometer (if available) Special Events Clinical Considerations Notes N/A PCP Medical Directives 35 Supraglottic Airway Medical Directive – AUXILIARY A Primary Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Need for ventilatory assistance OR airway control AND Other airway management is inadequate or ineffective Conditions Supraglottic Airway AGE: N/A LOA: N/A HR: N/A RR: N/A SBP: N/A Other: patient must be in cardiac arrest Contraindications Supraglottic Airway Active vomiting Inability to clear the airway Airway edema Stridor Caustic ingestion PCP Medical Directives 36 Intro Treatment Consider supraglottic airway insertion. The maximum number of attempts is 2. Confirm supraglottic airway placement: Method Secondary ETCO2 Chest rise Other PCP Method Primary Auscultation Clinical Considerations Notes Special Events ACP An attempt at supraglottic airway insertion is defined as the insertion of the supraglottic airway into the mouth. PCP Medical Directives 37 Nausea / Vomiting Medical Directive – AUXILIARY A Primary Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Nausea OR vomiting Conditions Dimenhydrinate AGE: N/A WEIGHT: ≥25 kg LOA: Unaltered HR: N/A RR: N/A SBP: N/A Other: N/A Contraindications Dimenhydrinate Allergy or sensitivity to dimenhydrinate or other antihistamines Overdose on antihistamines or anticholinergics or tricyclic antidepressants PCP Medical Directives 38 Intro Treatment Consider dimenhydrinate: Weight ≥50 kg Route IV 50 mg 50 mg N/A 1 Route IM 50 mg 50 mg N/A 1 PCP Dose Max. single dose Dosing interval Max. # of doses Weight ≥25 kg to <50 kg Route Route IV IM 25 mg 25 mg 25 mg 25 mg N/A N/A 1 1 Clinical Considerations IV administration of dimenhydrinate applies only to PCPs certified to the level of PCP Autonomous IV. Notes Special Events ACP Prior to IV administration, dilute dimenhydrinate (concentration of 50 mg/1 ml) 1:9 with normal saline or sterile water. If given IM do not dilute. PCP Medical Directives 39 Electronic Control Device Probe Removal Medical Directive – AUXILIARY A Primary Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Electronic Control Device probe(s) embedded in patient. Conditions Probe Removal AGE: ≥18 years LOA: Unaltered HR: N/A RR: N/A SBP: N/A Other: N/A Contraindications Probe removal Probe embedded above the clavicles, in the nipple(s), or in the genital area. Treatment Consider probe removal Clinical Considerations Police may require preservation of the probe(s) for evidentiary purposes. This directive is for removal of ECD only and in no way constitutes treat and release, normal principles of patient assessment and care apply. PCP Medical Directives 40 A Primary Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Intro Analgesia Medical Directive – AUXILIARY Indications Isolated Hip OR Extremity Trauma AND Pain Acetaminophen PCP Conditions Ibuprofen ≥18 years AGE: ≥18 and <50 years LOA: Unaltered LOA: Unaltered HR: N/A HR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A Other: N/A Other: N/A ACP AGE: Contraindications Ibuprofen Acetaminophen Acetaminophen use within previous 4 hours Ibuprofen or NSAID use within previous 6 hours Allergy or sensitivity to acetaminophen Active vomiting Signs or symptoms of intoxication Major burns Special Events Allergy or sensitivity to ASA or NSAIDs Current active bleeding Active vomiting Hx of peptic ulcer disease or GI bleed Major burns Pregnant Hx of liver disease Hx cardiovascular disease If asthmatic, no prior use of ASA or other NSAIDs Notes CVA or TBI in the previous 24 hours PCP Medical Directives 41 Treatment Consider acetaminophen: Route PO Dose Max. single dose 960–1000 mg 1000 mg Dosing interval N/A Max. # of doses 1 Consider ibuprofen: Route PO Dose 400 mg Max. single dose 400 mg Dosing interval N/A Max. # of doses 1 Clinical Considerations Whenever possible, both acetaminophen and ibuprofen should be used together. PCP Medical Directives 42 A Primary Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Intro Moderate to Severe Pain Medical Directive – AUXILIARY Indications PCP Moderate to Severe pain AND Isolated hip or extremity trauma OR major burns OR current history of cancer related pain OR renal colic with prior history OR patients with acute musculoskeletal back strain. Conditions AGE: ≥ 18 years and < 50 years LOA: Unaltered HR: N/A RR: N/A SBP: Normotension Other: ACP Ketoralac Patient must remain NPO or is unable to take oral medications Contraindications Special Events Ketoralac NSAID or ibuprofen use within previous 6 hours Allergy or sensitivity to ASA or NSAIDs Patient on anticoagulation therapy Current active bleeding CVA or TBI in the previous 24 hours If asthmatic, no prior use of ASA or other NSAIDs Pregnant Notes Known renal impairment PCP Medical Directives 43 Treatment Consider Ketorolac: Route IM/IV Dose 30 mg Max. single dose 30mg Dosing interval N/A Max. # of doses 1 Clinical Considerations IV administration of ketorolac applies only to PCPs certified to the level of PCP Autonomous IV. PCP Medical Directives 44 Intro PCP Notes Special Events ACP Page Left Blank Intentionally PCP Medical Directives 45 Page Left Blank Intentionally PCP Medical Directives 46 Intro PCP Notes Special Events ACP Page Left Blank Intentionally PCP Medical Directives 47 Page Left Blank Intentionally PCP Medical Directives 48 Intro PCP Notes Special Events ACP Page Left Blank Intentionally PCP Medical Directives 49 Page Left Blank Intentionally PCP Medical Directives 50 Intro PCP ACP Notes Special Events ACP MEDICAL DIRECTIVES ACP Medical Directives ACP Medical Directives Table of Contents ACP Core Medical Directives Medical Cardiac Arrest Medical Directive ......................................................................... 3 Trauma Cardiac Arrest Medical Directive ......................................................................... 9 Hypothermia Cardiac Arrest Medical Directive ............................................................... 13 Foreign Body Airway Obstruction Cardiac Arrest Medical Directive ................................ 15 Neonatal Resuscitation Medical Directive ....................................................................... 17 Return of Spontaneous Circulation (ROSC) Medical Directive .......................................... 19 Cardiac Ischemia Medical Directive ................................................................................. 22 Acute Cardiogenic Pulmonary Edema Medical Directive .................................................. 24 Cardiogenic Shock Medical Directive ............................................................................... 26 Symptomatic Bradycardia Medical Directive ................................................................... 28 Tachydysrhythmia Medical Directive … ............................................................................ 30 Intravenous and Fluid Therapy Medical Directive ............................................................ 33 Pediatric Intraosseous Medical Directive ......................................................................... 36 Hypoglycemia Medical Directive ...................................................................................... 37 Seizure Medical Directive ................................................................................................. 40 Opioid Toxicity Medical Directive .................................................................................... 42 Orotracheal Intubation Medical Directive ........................................................................ 44 Bronchoconstriction Medical Directive ............................................................................ 46 Moderate to Severe Allergic Reaction Medical Directive ................................................ 49 Croup Medical Directive .................................................................................................. 51 Tension Pneumothorax Medical Directive........................................................................ 53 Pain Medical Directive ..................................................................................................... 54 Pediatric Pain Medical Directive ..................................................................................... 56 ACP Auxiliary Medical Directives Adult Intraosseous Medical Directive – AUXILIARY............................................................. 58 Central Venous Access Device Access Medical Directive – AUXILIARY ............................... 59 Continuous Positive Airway Pressure (CPAP) Medical Directive – AUXILIARY .................... 60 Supraglottic Airway Medical Directive – AUXILIARY ........................................................... 62 Cricothyrotomy Medical Directive – AUXILIARY ................................................................. 64 Nausea/Vomiting Medical Directive – AUXILIARY............................................................... 66 Combative Patient Medical Directive – AUXILIARY ............................................................. 68 Procedural Sedation Medical Directive – AUXILIARY .......................................................... 70 Electronic Control Device Probe Removal Medical Directive – AUXILIARY ......................... 72 Analgesia Medical Directive – AUXILIARY ........................................................................... 73 Moderate to Severe Pain Medical Directive – AUXILIARY .................................................. 75 Nasotracheal Intubation Medical Directive – AUXILIARY ................................................... 77 Blank pages left for future Medical Directives ....................................................................... 80 ACP Medical Directives 2 Intro Medical Cardiac Arrest Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Non-traumatic cardiac arrest Conditions AGE: ≥30 days AGE: ≥8 years Altered LOA: Altered LOA: Altered LOA: HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A VF or pulseless VT Other: Shock indicated Other: performed in 2 minute increments Other: Alternative to manual defibrillation Amiodarone Epinephrine PCP N/A ACP AGE: AED Defibrillation Manual Defibrillation Lidocaine ≥30 days AGE: ≥30 days AGE: ≥30 days LOA: Altered LOA: Altered LOA: Altered HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: If anaphylaxis suspected as causative event, IM route may be used Other: VF or pulseless VT Other: VF or pulseless VT where amiodarone is not available Notes AGE: Special Events CPR ACP Medical Directives 3 0.9% NaCl Fluid Bolus AGE: N/A LOA: Altered HR: N/A RR: N/A SBP: N/A Other: PEA Any other rhythm where hypovolemia is suspected Contraindications CPR Obviously dead as per BLS standards Manual Defibrillation Rhythms other than VF or pulseless VT AED Defibrillation Non-shockable rhythm Meet conditions of DNR standard Epinephrine Allergy or sensitivity to epinephrine Amiodarone Allergy or sensitivity to amiodarone Lidocaine Allergy or sensitivity to lidocaine Use / Availability of amiodarone 0.9% NaCl Fluid Bolus Fluid overload ACP Medical Directives 4 Intro Treatment Consider CPR Consider supraglottic airway insertion: where more than OPA/NPA and BVM required and without interrupting CPR. Consider Manual defibrillation: Dose Age ≥8 years PCP Age ≥30 days to <8 years 1 shock 1 shock As per BH / manufacturer As per BH / manufacturer 2 J/kg Subsequent and max. dose(s) 4 J/kg Dosing interval 2 min 2 min Max. # of doses N/A N/A ACP First dose Consider AED defibrillation (alternative to manual defibrillation): Age Age ≥30 days to <8 years ≥8 years 1 shock 1 shock 1 shock As per BH / manufacturer As per BH / manufacturer As per BH / manufacturer Dosing interval N/A N/A N/A Max. # of doses N/A N/A N/A Max. single dose Notes Dose Without Ped attenuator Special Events With Ped attenuator ACP Medical Directives 5 Consider epinephrine: In the event anaphylaxis is suspected as the causative event of the cardiac arrest, a single dose of 0.01 mg/kg 1:1,000 solution, to a maximum of 0.5 mg IM, may be given prior to obtaining the IV/IO. Age ≥12 years Route Route IV / IO ETT IV / IO / CVAD ETT 1:10,000 1:1,000 1:10,000 As per BH 0.01 mg/kg 0.1 mg/kg to a max of 2 mg 1 mg 2 mg Solution Dose Age ≥30 days to <12 years Min. single dose 0.1 mg 1 mg 1 mg 2 mg Dosing interval 4 min. 4 min. 4 min. 4 min. Max. # of doses N/A N/A N/A N/A * The epinephrine dose may be rounded to the nearest 0.05 mg. Consider amiodarone: Age ≥30 days to <12 years Route IV / IO Route IV / IO / CVAD 5 mg/kg 300 mg Max. initial dose 300 mg 300 mg Repeat dose 5 mg/kg 150 mg Max. repeat dose 150 mg 150 mg Dosing interval 4 min. 4 min. Max. # of doses 2 2 Initial Dose ACP Medical Directives 6 Age ≥12 years Age Age ≥12 years Route IV / IO / CVAD ETT 1 mg/kg 2 mg/kg 1.5 mg/kg 3 mg/kg Min. single dose N/A N/A N/A N/A Dosing interval 4 min. 4 min. 4 min. 4 min. Max. # of doses 2 2 2 2 PCP ≥30 days to 12 years and <40 kg Route IV / IO ETT Dose Intro Consider lidocaine (if amiodarone not available): Infusion interval Reassess every Max. volume Age ≥12 years Route IV / IO Route IV / IO / CVAD 20 ml/kg 20 ml/kg Immediate Immediate 100 ml 250 ml 20 ml/kg up to 2,000 ml 2,000 ml Special Events Infusion Age ≥30 days to <12 years ACP Consider 0.9% NaCl fluid bolus: Consider intubation: if the airway is not being adequately managed. MANDATORY PROVINCIAL PATCH POINT: Notes Patch to BHP following 3 rounds of epinephrine (or after 3rd analyses if no IV/IO/ETT access). If the BH patch fails, transport to the closest appropriate receiving hospital following the 4th epinephrine administration (or 4th analysis if no IV/IO/ETT access). ACP Medical Directives 7 Clinical Considerations In unusual circumstances (e.g.: pediatric patients or toxicological overdoses), consider initiating transportation following the first rhythm analysis that does not result in a defibrillation being delivered. The IV and IO routes of medication administration are preferred over the ETT route. However, ETT administration may be used if the IV/IO routes are delayed (e.g. >5 min.) ACP Medical Directives 8 Intro Trauma Cardiac Arrest Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Cardiac arrest secondary to severe blunt or penetrating trauma Conditions AGE: N/A AGE: ≥30 days AGE: ≥30 days LOA: Altered LOA: Altered LOA: Altered HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: N/A Other: VF or pulseless VT Other: Shock indicated PCP AED Defibrillation Manual Defibrillation ACP CPR AGE: ≥16 years LOA: Altered HR: 0 RR: 0 SBP: N/A Other: No palpable pulses Special Events Trauma TOR Notes No defibrillation delivered AND monitored HR =0 (asystole) OR monitored HR >0 AND the closest ER ≥30 min transport time away. ACP Medical Directives 9 Contraindications CPR Manual Defibrillation Obviously dead as per BLS standards Rhythms other than VF or pulseless VT AED Defibrillation Non-shockable rhythm Meet conditions of DNR standard Trauma TOR Age <16 years Shock delivered Monitored HR >0 and closest ER <30 min away Treatment Consider CPR Consider Manual defibrillation: Dosing interval N/A Age ≥8 years 1 shock As per BH / manufacturer N/A Max. # of doses 1 1 Dose Initial dose Age ≥30 days to <8 years 1 shock 2 J/kg ACP Medical Directives 10 Age ≥30 days to <8 years ≥8 years With Ped attenuator 1 shock Without Ped attenuator 1 shock 1 shock As per BH / manufacturer As per BH / manufacturer As per BH / manufacturer Dosing interval N/A N/A N/A Max. # of doses 1 1 1 Dose Max. single dose PCP Age Intro Consider AED defibrillation (alternative to manual defibrillation): MANDATORY PROVINCIAL PATCH POINT: ACP Patch to BHP for authorization to apply the Trauma (TOR) Termination of Resuscitation if applicable. If the BH patch fails, or the trauma TOR does not apply, transport to the closest appropriate receiving hospital following the first analysis/shock. Clinical Considerations Notes Special Events If no obvious external signs of significant blunt trauma, consider medical cardiac arrest and treat according to the appropriate medical cardiac arrest directive. ACP Medical Directives 11 Treatment – Algorithm for Trauma Arrest INDICATIONS: Cardiac arrest secondary to severe blunt or penetrating trauma CPR (throughout duration of call) Apply defib pads to all patient =30 days of age – Rhythm analysis VF or VT Defibrillation: 1 shock, Max # doses = 1 YES YES PEA (HR >0) Asystole YES YES NO Pt age =16 yrs YES YES Drive time to closest ER >30 min NO YES NO Patch YES NO Transport to ED TOR implemented ACP Medical Directives 12 Transport to Emergency Department YES Other monitored rhythm Intro Hypothermia Cardiac Arrest Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Cardiac arrest secondary to severe hypothermia AED Defibrillation Manual Defibrillation AGE: N/A AGE: ≥30 days AGE: ≥30 days LOA: Altered LOA: Altered LOA: Altered HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: N/A Other: VF or pulseless VT Other: Shock indicated ACP CPR PCP Conditions Contraindications Obviously dead as per BLS standards Manual Defibrillation Rhythms other than VF or pulseless VT AED Defibrillation Special Events CPR Non-shockable rhythm Meet conditions of DNR standard Treatment Notes Consider CPR ACP Medical Directives 13 Consider Manual defibrillation: Dose Age ≥30 days to <8 years 1 shock Age ≥8 years Dosing interval N/A 1 shock As per BH / manufacturer N/A Max. # of doses 1 1 Initial dose 2 J/kg Consider AED defibrillation (alternative to manual defibrillation): Age ≥30 days to <8 years Age ≥8 years With Ped attenuator Without Ped attenuator 1 shock 1 shock 1 shock As per BH / manufacturer As per BH / manufacturer As per BH / manufacturer Dosing interval N/A N/A N/A Max. # of doses 1 1 1 Dose Max. single dose Transport to the closest appropriate facility without delay following the first analysis. Clinical Considerations N/A ACP Medical Directives 14 Intro Foreign Body Airway Obstruction Cardiac Arrest Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Cardiac arrest secondary to an airway obstruction AED Defibrillation Manual Defibrillation AGE: N/A AGE: ≥30 days AGE: ≥30 days LOA: Altered LOA: Altered LOA: Altered HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: N/A Other: VF or pulseless VT Other: Shock indicated ACP CPR PCP Conditions Contraindications Obviously dead as per BLS standards Manual Defibrillation Rhythms other than VF or pulseless VT AED Defibrillation Special Events CPR Non-shockable rhythm Meet conditions of DNR standard Treatment Notes Consider CPR ACP Medical Directives 15 Consider foreign body removal: (utilizing BLS maneuvers and/or laryngoscope and Magill forceps). Consider Manual defibrillation: Age ≥30 days to <8 years 1 shock Dose Initial dose Age ≥8 years 1 shock As per BH / manufacturer N/A 1 2 J/kg Dosing interval Max. # of doses N/A 1 Consider AED defibrillation (alternative to manual defibrillation): Age Age ≥30 days to <8 years ≥8 years With Ped attenuator Without Ped attenuator 1 shock 1 shock 1 shock As per BH / manufacturer As per BH / manufacturer As per BH / manufacturer Dosing interval N/A N/A N/A Max. # of doses 1 1 1 Dose Max. single dose If the obstruction cannot be removed, transport to the closest appropriate facility without delay following the first analysis. If the patient is in cardiac arrest following removal of the obstruction, initiate management as a medical cardiac arrest. Clinical Considerations N/A ACP Medical Directives 16 Intro Neonatal Resuscitation Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Severe cardio-respiratory distress Conditions AGE: Newborn or <30 days of age LOA: N/A HR: N/A RR: N/A SBP: N/A Other: Less than full term, or meconium, or poor APGAR score ACP PCP Resuscitation Contraindications Resuscitation Special Events Clear of meconium Breathing or crying Good muscle tone Notes Pink in colour ACP Medical Directives 17 Treatment Birth: Routine Care: Clear of *meconium? Breathing or crying? Good muscle tone? Colour pink? Term gestation YES Provide warmth Clear airway if necessary Do not routinely suction Dry Ongoing evaluation NO Provide warmth Position/clear airway (as necessary) Dry, stimulate, reposition 30 Sec Evaluate respirations, heart rate and colour Breathing Supportive care HR ≥100 + pink Apnea, gasping or HR <100 60 Sec Provide positive pressure ventilation (BVM) using air HR <60 90 Sec Supportive care HR ≥100 + pink HR ≥60 Provide positive pressure ventilation (BVM/ETT) using 100% oxygen Administer chest compressions HR <60 120 Sec Ventilating HR ≥60 Epinephrine: 0.01 mg/kg (0.1 ml/kg) 1:10,000 IV/IO OR 0.1 mg/kg (1ml/kg) 1:10,000 ETT q4 minutes. Indicate transport prior to the 3rd dose if possible *if meconium is present and baby not vigorous, suction mouth and pharynx, consider ETT and provide BVM ventilations as required and then continue with the remainder of the initial steps following birth. ACP Medical Directives 18 Intro Return of Spontaneous Circulation (ROSC) Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Patient with return of spontaneous circulation (ROSC) after the resuscitation was initiated. PCP Conditions N/A AGE: N/A LOA: N/A LOA: N/A HR: N/A HR: N/A RR: N/A RR: N/A SBP: Hypotension SBP: Hypotension Other: Chest auscultation is clear Other: N/A AGE: Males ≥18 years Females ≥50 years LOA: Altered HR: N/A RR: N/A SBP: ≥90 mmHg (spontaneous, following bolus administered or with dopamine) Other: N/A Notes AGE: Therapeutic Hypothermia ACP Dopamine Special Events 0.9% NaCl Fluid Bolus ACP Medical Directives 19 Contraindications 0.9% NaCl Fluid Bolus Fluid overload SBP ≥90 mmHg Dopamine Therapeutic Hypothermia Allergy or sensitivity to dopamine Traumatic cardiac arrest (blunt, penetrating or burn) Tachydysrhythmias excluding sinus tachycardia Sepsis or serious infection suspected as cause of arrest Mechanical shock states Hypovolemia Pheochromocytoma Hypothermic arrest Known coagulopathy (medical history or medications) SBP ≥ 90 mmHg Treatment Consider rapid transport Consider optimizing ventilation and oxygenation: Titrate oxygenation ≥94% Avoid hyperventilation and target an ETCO2 of 35–40 mmHg with continuous waveform capnography (if available) ACP Medical Directives 20 Age ≥12 years Route IV 10 ml/kg Infusion interval Immediate Immediate Reassess every Max. volume 100 ml 250 ml 1,000 ml 1,000 ml PCP Infusion Age <12 years Route IV 10 ml/kg Intro Consider 0.9% NaCl fluid bolus: Initial Infusion Rate Titration increment Titration interval Route IV 5 mcg/kg/min 5 mcg/kg/min 5 min. Max infusion rate 20 mcg/kg/min ACP Consider dopamine: Consider 12 lead acquisition (if available) Special Events Consider Therapeutic hypothermia (if available) Clinical Considerations Notes The application of therapeutic hypothermia should not detract from rapid transport, optimizing ventilation and oxygenation or the management of a re-arrest. ACP Medical Directives 21 Cardiac Ischemia Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Suspected cardiac ischemia Conditions Nitroglycerin ASA Morphine AGE: ≥18 years AGE: ≥18 years AGE: ≥18 years LOA: Unaltered LOA: Unaltered LOA: Unaltered HR: N/A HR: 60–159 bpm HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: Normotension SBP: Normotension Other: Able to chew and swallow Other: Prior history of nitroglycerin use or IV access obtained Other: N/A Contraindications ASA Nitroglycerin Allergy or sensitivity to ASA or NSAIDS Allergy or sensitivity to nitrates Allergy or sensitivity to morphine If asthmatic, no prior use of ASA Phosphodiesterase inhibitor use within the previous 48 hours Injury to the head or chest or abdomen OR pelvis SBP drops by one third or more of its initial value after nitroglycerin is administered SBP drops by one-third or more of its initial value after morphine is administered Current active bleeding CVA or TBI in the previous 24 hours 12-lead ECG compatible with Right Ventricular infarct ACP Medical Directives 22 Morphine Intro Treatment Consider ASA: Dose Max. single dose Dosing interval Max. # of doses PCP Route PO 160–162 mg 162 mg N/A 1 Consider 12-lead ECG acquisition (if available) Consider nitroglycerin: ACP Dose Max. single dose Dosing interval Max. # of doses SBP ≥100 mmHg Route SL 0.3 or 0.4 mg 0.4 mg 5 min. 6 Dose Max. single dose Dosing interval Max. # of doses Special Events Consider morphine (after the third dose of nitroglycerin or if nitroglycerin is contraindicated): Route IV 2 mg 2 mg 5 min. 5 Clinical Considerations Notes N/A ACP Medical Directives 23 Acute Cardiogenic Pulmonary Edema Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Moderate to severe respiratory distress AND Suspected acute cardiogenic pulmonary edema Conditions Nitroglycerin AGE: ≥18 years LOA: N/A HR: 60–159 bpm RR: N/A SBP: Normotension Other: Ascertain prior history of nitroglycerin use OR establish IV access Contraindications Nitroglycerin Allergy or sensitivity to nitrates Phosphodiesterase inhibitor use within the previous 48 hours SBP drops by one third or more of its initial value after nitroglycerin is administered ACP Medical Directives 24 Intro Treatment Consider nitroglycerin: SBP ≥140 mmHg IV or Hx No Route SL 0.3 or 0.4 mg 0.4 mg 5 min. 6 IV or Hx Yes Route SL 0.6 or 0.8 mg 0.8 mg 5 min. 6 PCP Dose Max. single dose Dosing interval Max. # of doses SBP 100 mmHg to <140 mmHg IV or Hx Yes Route SL 0.3 or 0.4 mg 0.4 mg 5 min. 6 NOTE: Hx refers to a patient with a prior history of nitroglycerin use. ACP Consider 12-lead ECG acquisition (if available) Clinical Considerations Notes Special Events N/A ACP Medical Directives 25 Cardiogenic Shock Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications STEMI-positive ECG AND Cardiogenic shock Conditions Dopamine 0.9% NaCl AGE: N/A AGE: N/A LOA: N/A LOA: N/A HR: N/A HR: N/A RR: N/A RR: N/A SBP: Hypotension SBP: Hypotension Other: Clear chest on auscultation Other: N/A Contraindications 0.9% NaCl N/A Dopamine Allergy or sensitivity to dopamine Tachydysrhythmias excluding sinus tachycardia Mechanical shock states Pheochromocytoma ACP Medical Directives 26 Intro Treatment Consider 0.9% NaCl fluid bolus: Infusion Age ≥18 years Route Route IV IO 10 ml/kg 10 ml/kg 10 ml/kg 10 ml/kg Infusion interval N/A N/A N/A N/A Reassess every 100 ml 100 ml 250 ml 250 ml 10 ml/kg 10 ml/kg 10 ml/kg 10 ml/kg Max. volume PCP Age <18 years Route Route IV IO NOTE: If NaCl bolus contraindicated due to pulmonary crackles, consider dopamine. Consider dopamine: Initial infusion rate 5 mcg/kg/min. Titration increment 5 mcg/kg/min. Titration interval 5 min. Max. infusion rate 20 mcg/kg/min. ACP Route IV Special Events NOTE: Titrate dopamine to achieve a systolic BP of 90–110 mmHg. If discontinuing dopamine electively, do so gradually over 5–10 minutes. Clinical Considerations Notes Contact BHP if patient is bradycardic with respect to age. ACP Medical Directives 27 Symptomatic Bradycardia Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Bradycardia AND Hemodynamic instability Conditions Atropine Transcutaneous Pacing Dopamine AGE: ≥18 years AGE: ≥18 years AGE: ≥18 years LOA: N/A LOA: N/A LOA: N/A HR: < 50 bpm HR: < 50 bpm HR: < 50 bpm RR: N/A RR: N/A RR: N/A SBP: Hypotension SBP: Hypotension SBP: Hypotension Other: N/A Other: N/A Other: N/A Contraindications Atropine Transcutaneous Pacing Dopamine Allergy or sensitivity to atropine Hemodynamic stability Allergy or hypersensitivity to dopamine Hypothermia Hemodynamic stability Hemodynamic stability Hypothermia Pheochromocytoma History of heart transplant Treatment Consider Rhythm determination ACP Medical Directives 28 Intro Consider 12 lead ECG acquisition (if available and won’t delay therapy) Consider atropine: PCP Dose Max. single dose Dosing interval Max. # of doses Route IV 0.5 mg 0.5 mg 5 min. 2 MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to proceed with transcutaneous pacing and/or a dopamine infusion. Consider transcutaneous pacing Consider dopamine: ACP Initial infusion rate Titration increment Titration interval Max. infusion rate Route IV 5 mcg/kg/min. 5 mcg/kg/min. 5 min. 20 mcg/kg/min. Special Events NOTE: Titrate dopamine to achieve a systolic BP of 90–110 mmHg. If discontinuing dopamine electively, do so gradually over 5–10 minutes. Clinical Considerations Atropine may be beneficial in the setting of sinus bradycardia, atrial fibrillation, first degree AV block, or second-degree Type I AV block. A single dose of atropine should be considered for second degree Type II or third degree AV blocks with fluid bolus while preparing for TCP OR if there is a delay in implementing TCP OR if TCP is unsuccessful. Notes The dopamine infusion should be initiated at 5 mcg/kg/min. and titrated upward to effect in increments of 5 mcg/kg/min every 5 minutes up to a maximum of 20 mcg/kg/min. The desired effect is a SBP of 90–110 mmHg. ACP Medical Directives 29 Tachydysrhythmia Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Symptomatic Tachydysrhythmia Conditions Adenosine Valsalva Maneuver AGE: ≥18 years AGE: ≥18 years AGE: ≥18 years LOA: Unaltered LOA: Unaltered LOA: Unaltered HR: ≥150 HR: ≥150 HR: ≥120 RR: N/A RR: N/A RR: N/A SBP: Normotension SBP: Normotension SBP: Normotension Other: Narrow complex and regular rhythm Other: Narrow complex and regular rhythm Lidocaine Other: Wide complex and regular rhythm Synchronized Cardioversion AGE: ≥18 years AGE: ≥18 years LOA: Unaltered LOA: N/A HR: ≥120 HR: ≥120 (wide) or ≥150 (narrow) RR: N/A RR: N/A SBP: Normotension SBP: Hypotension Other: Wide complex and regular rhythm Other: Altered mental status, ongoing chest pain, other signs of shock ACP Medical Directives 30 Amiodarone Valsalva Maneuver Sinus tachycardia or atrial fibrillation or atrial flutter Intro Contraindications Amiodarone Adenosine Allergy or sensitivity to amiodarone Allergy or sensitivity to adenosine Sinus tachycardia or atrial fibrillation or atrial flutter PCP Patient taking dipyridamole or carbamazepine Bronchoconstriction on exam Lidocaine Synchronized Cardioversion Allergy or sensitivity to lidocaine N/A ACP Treatment Consider Rhythm determination: Confirm regularity. Consider 12 lead ECG acquisition: To confirm QRS width (if available and won’t delay therapy). Special Events Consider valsalva maneuver: Perform a maximum of two attempts lasting 10 to 20 seconds duration each. Consider adenosine: Notes Initial Dose Second dose Dosing interval Max. # of doses Route IV 6 mg 12 mg 2 min. 2 doses ACP Medical Directives 31 MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to proceed with amiodarone or lidocaine or if monomorphic wide complex regular rhythm for adenosine. Consider amiodarone (if available) OR lidocaine: Drug Amiodarone Route IV* Drug Lidocaine Route IV First Dose Subsequent Dose(s) 150 mg 150 mg 1.5 mg/kg 0.75 mg/kg Max. single dose Dosing interval Max. # of doses 150 mg 10 min. 2 150 mg 10 min. 3 *Amiodarone should be administered by IV infusion over 10 min. MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to proceed with synchronized cardioversion Consider synchronized cardioversion: Administer up to three synchronized shocks in accordance with BHP direction and energy settings. (In the setting of a patch failure, the energy settings to be used are 100 J, 200 J and the maximum manufacturer setting.) Clinical Considerations N/A ACP Medical Directives 32 Intro Intravenous and Fluid Therapy Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Actual or potential need for intravenous medication OR fluid therapy IV N/A ≥2 years for PCP Assist IV LOA: N/A HR: N/A RR: N/A SBP: N/A Other: N/A Fluid Bolus AGE: N/A LOA: N/A HR: N/A RR: N/A SBP: Hypotension Other: N/A ACP AGE: PCP Conditions Contraindication Suspected fracture proximal to the access site. Fluid Bolus Special Events IV Signs of fluid overload Treatment Notes Consider IV cannulation ACP Medical Directives 33 Consider 0.9% NaCl maintenance infusion: Age <12 years Age ≥12 years Route IV / IO Route IV / IO / CVAD 15 ml/hr 30–60 ml/hr Infusion interval N/A N/A Reassess every N/A N/A Max. volume N/A N/A Infusion MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to administer IV NaCl bolus to patients <12 years with suspected Diabetic Ketoacidosis (DKA) Consider 0.9% NaCl fluid bolus: Infusion Age <12 years Route IV / IO 20 ml/kg Age ≥12 years Route IV / IO / CVAD 20 ml/kg Infusion interval Immediate Immediate Reassess every 100 ml 250 ml Max. volume* 20 ml/kg up to 2,000 ml 2,000 ml *The maximal volume of NaCl is lower for patients in cardiogenic shock. Clinical Considerations “PCP Assist IV” authorizes a PCP to cannulate a peripheral IV at the request and under the direct supervision of an ACP. The ACP will perform all IV further therapy in accordance with the Intravenous Access and Fluid Administration Medical Directive once intravenous access is obtained. PCPs certified in PCP Assist IV are not authorized to administer IV fluid or medication therapy. ACP Medical Directives 34 Intro Adult IO and CVAD procedures are auxiliary medical directives described elsewhere. Fluid administration via the IO or CVAD routes only apply to paramedics certified and authorized to perform these procedures. Notes Special Events ACP PCP Microdrips and or volume control administration sets should be considered when IV access is indicated for patients less than 12 years of age. ACP Medical Directives 35 Pediatric Intraosseous Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Actual or potential need for intravenous medication OR fluid therapy AND Intravenous access is unobtainable AND Cardiac arrest or near-arrest state Conditions IO AGE: <12 years LOA: N/A HR: N/A RR: N/A SBP: N/A Other: N/A Contraindication IO Fracture or crush injuries or suspected or known replacement / prosthesis proximal to the access site. Treatment Consider IO access Clinical Considerations N/A ACP Medical Directives 36 Intro Hypoglycemia Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Agitation OR altered LOA OR seizure OR symptoms of stroke Conditions N/A AGE: N/A LOA: Altered LOA: Altered HR: N/A HR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A Other: Hypoglycemia Other: Hypoglycemia ACP AGE: PCP Glucagon Dextrose Contraindications Dextrose Allergy or sensitivity to dextrose Glucagon Allergy or sensitivity to glucagon Special Events Pheochromocytoma Treatment Notes Perform glucometry ACP Medical Directives 37 Consider dextrose or glucagon: Weight N/A Drug Dextrose Age ≥30 days to <2 years Weight N/A Concentration D10W Route IV 0.2 g/kg (2 ml/kg) 5 g (50 ml) Concentration D25W Route IV 0.5 g/kg (2 ml/kg) 10 g (40 ml) Concentration D50W Route IV 0.5 g/kg (1 ml/kg) 25 g (50 ml) Dosing interval 10 min. 10 min. 10 min. Max. # of doses 2 2 2 Age <30 days Dose Max. single dose Age ≥2 years Weight N/A Drug Glucagon Age N/A Weight <25 kg Concentration N/A Route IM 0.5 mg Weight ≥25 kg Concentration N/A Route IM 1.0 mg Max. single dose 0.5 mg 1.0 mg Dosing interval 20 min. 20 min. Max. # of doses 2 2 Dose ACP Medical Directives 38 If the patient responds to dextrose or glucagon, he/she may receive oral glucose or other simple carbohydrates. Intro Clinical Considerations If only mild signs or symptoms are exhibited, the patient may receive oral glucose or other simple carbohydrates instead of dextrose or glucagon. Notes Special Events ACP PCP If a patient initiates an informed refusal of transport, a final set of vital signs including blood glucometry must be attempted. ACP Medical Directives 39 Seizure Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Active generalized motor seizure Conditions Midazolam AGE: N/A LOA: Unresponsive HR: N/A RR: N/A SBP: N/A Other: N/A Contraindications Midazolam Allergy or sensitivity to midazolam Hypoglycemia ACP Medical Directives 40 Intro Treatment Consider midazolam: Dose Route IV 0.1 mg/kg Route IM 0.2 mg/kg Route IN 0.2 mg/kg Route Buccal 0.2 mg/kg 5.0 mg 10 mg 10 mg 10 mg Dosing interval 5 min. 5 min. 5 min. 5 min. Max. # of doses 2 2 2 2 PCP Max. single dose Clinical Considerations Notes Special Events ACP Conditions such as cardiac arrest and hypoglycemia often present as seizure and should be considered by a paramedic. ACP Medical Directives 41 Opioid Toxicity Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Altered LOC AND Respiratory depression AND Suspected opioid overdose Conditions Naloxone AGE: ≥18 years LOA: Altered HR: N/A RR: < 10 SBP: N/A Other: N/A Contraindications Naloxone Allergy or sensitivity to naloxone Uncorrected hypoglycemia Treatment MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to proceed with naloxone ACP Medical Directives 42 Dose Max. single dose Dosing interval Max. # of doses Route SC 0.8 mg 0.8 mg N/A 1 Route IM 0.8 mg 0.8 mg N/A 1 Route IN 0.8 mg 0.8 mg N/A 1 Intro Consider naloxone: Route IV* Up to 0.4 mg 0.4 mg N/A 1 PCP *For the IV route, titrate naloxone only to restore the patient’s respiratory status. Clinical Considerations Notes Special Events ACP N/A ACP Medical Directives 43 Orotracheal Intubation Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Need for ventilatory assistance or airway control AND Other airway management is inadequate or ineffective Conditions Lidocaine Spray Orotracheal Intubation AGE: N/A AGE: N/A LOA: N/A LOA: N/A HR: N/A HR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A Other: Orotracheal / Intubation Other: N/A Contraindications Orotracheal Intubation Lidocaine Allergy or sensitivity to lidocaine Unresponsive patient Age <50 years AND current episode of asthma exacerbation AND not in or near cardiac arrest. ACP Medical Directives 44 Intro Treatment Consider topical lidocaine spray for “awake” orotracheal intubation (to the hypopharynx): Dosing interval N/A Max. # of doses 20 sprays PCP Dose Max. dose Route TOPICAL 10 mg/spray 5mg/kg Consider intubation: with or without intubation facilitation devices. The maximum number of intubation attempts is 2. Confirm orotracheal tube placement: Method Secondary ETCO2 EDD Other ACP Method Primary Visualization Auscultation Chest rise Clinical Considerations The maximum number of supraglottic airway attempts is two (2) and the maximum number of intubation attempts is two (2). At least two primary and one secondary ETT placement confirmation methods must be used. If the patient has a pulse, an ETCO2 device (quantitative or qualitative) must be used for ETT placement confirmation. Special Events An intubation attempt is defined as insertion of the laryngoscope blade into the mouth. Additional secondary ETT placement confirmation devices may be authorized by the local medical director. Notes ETT placement must be reconfirmed immediately after every patient movement. ACP Medical Directives 45 Bronchoconstriction Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Respiratory distress AND Suspected bronchoconstriction Conditions Salbutamol Epinephrine Epinephrine Autoinjector AGE: N/A AGE: LOA: N/A WEIGHT: N/A WEIGHT: ≥10 kg HR: N/A LOA: N/A LOA: N/A RR: N/A HR: N/A HR: N/A SBP: N/A RR: RR: Other: N/A BVM ventilation required BVM ventilation required SBP: N/A SBP: N/A Other: Hx of asthma Other: Hx of asthma N/A AGE: N/A Contraindications Salbutamol Allergy or sensitivity to salbutamol Epinephrine Allergy or sensitivity to epinephrine ACP Medical Directives 46 Epinephrine Autoinjector Allergy or sensitivity to epinephrine Intro Treatment Consider salbutamol: Weight ≥25 kg Route MDI (if available)* Dose Route Route MDI (if available)* NEB Route NEB Up to 600 mcg (6 puffs) 2.5 mg Up to 800 mcg (8 puffs) 5 mg 600 mcg 2.5 mg 800 mcg 5 mg 5–15 min. PRN 5–15 min. PRN 5–15 min. PRN 5–15 min. PRN 3 3 3 3 Max. single dose Dosing interval Max. # of doses PCP Weight <25 kg * 1 puff=100mcg IM Weight ≥10 kg to <25 kg Route Pediatric Autoinjector Weight ≥25 kg Route Adult Autoinjector Concentration 1:1,000 Concentration 1:1,000 Concentration 1:1,000 0.01 mg/kg** 1 injection (0.15 mg) 1 injection (0.3 mg) 0.5 mg 1 injection 1 injection Dosing interval N/A N/A N/A Max. # of doses 1 1 1 Dose Max. single dose Special Events Weight Any Route ACP Consider epinephrine: Notes **The epinephrine dose may be rounded to the nearest 0.05 mg. ACP Medical Directives 47 Clinical Considerations Epinephrine should be the first drug administered if the patient is apneic. Salbutamol MDI may be administered subsequently using a BVM MDI adapter (if available). Nebulization is contraindicated in patients with a known or suspected fever or in the setting of a declared febrile respiratory illness outbreak by the local medical officer of health. When administering salbutamol MDI, the rate of administration should be 100 mcg approximately every 4 breaths. A spacer should be used when administering salbutamol MDI (if available). MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to use pediatric autoinjector for patients <10 kg. ACP Medical Directives 48 Intro Moderate to Severe Allergic Reaction Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications PCP Exposure to a probable allergen AND Signs and/or symptoms of a moderate to severe allergic reaction (including anaphylaxis) Conditions N/A AGE: Diphenhydramine AGE: N/A N/A WEIGHT: N/A WEIGHT: ≥10 kg WEIGHT: ≥25 kg LOA: N/A LOA: N/A LOA: N/A HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: For anaphylaxis only Other: For anaphylaxis only Other: N/A ACP AGE: Epinephrine Autoinjector Special Events Epinephrine Contraindications Allergy or sensitivity to epinephrine Epinephrine Autoinjector Allergy or sensitivity to epinephrine Diphenhydramine Allergy or sensitivity to diphenhydramine Notes Epinephrine ACP Medical Directives 49 Treatment Consider epinephrine: Weight N/A Route Weight ≥10 kg to <25 Route Pediatric Autoinjector Concentration 1:1,000 Weight ≥25 kg Route Adult Autoinjector Concentration 1:1,000 0.01 mg/kg* 1 injection (0.15 mg) 1 injection (0.3 mg) IM Concentration 1:1,000 Dose Max. single dose 0.5 mg 1 injection 1 injection Dosing interval N/A N/A N/A Max. # of doses 1 1 1 * The epinephrine dose may be rounded to the nearest 0.05 mg. Consider diphenhydramine (if available): Dose Max. single dose Dosing interval Max. # of doses Weight ≥25 kg to <50 kg Route Route IV IM 25 mg 25 mg 25 mg 25 mg N/A N/A 1 1 Weight ≥50 kg Route Route IV IM 50 mg 50 mg 50 mg 50 mg N/A N/A 1 1 Clinical Considerations Epinephrine should be the first drug administered in anaphylaxis. MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to use pediatric autoinjector for patients <10kg ACP Medical Directives 50 Intro Croup Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications PCP Severe respiratory distress AND Stridor at rest AND Current history of URTI AND Barking cough OR recent history of a barking cough Conditions <8 years LOA: N/A HR: <200 bpm RR: N/A SBP: N/A Other: N/A Special Events AGE: ACP Epinephrine Contraindications Epinephrine Notes Allergy or sensitivity to epinephrine ACP Medical Directives 51 Treatment Consider epinephrine: Age Weight <5 kg Route NEB Concentration 1:1,000 0.5 mg 0.5 mg Weight ≥5 kg Route NEB Concentration 1:1,000 2.5 mg 2.5 mg Age ≥1 year to <8 years Weight N/A Route NEB Concentration 1:1,000 5 mg 5 mg Dosing interval N/A N/A N/A Max. # of doses 1 1 1 <1 year Dose Max. single dose Clinical Considerations The minimum initial volume for nebulization is 2.5 ml. ACP Medical Directives 52 Intro Tension Pneumothorax Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications PCP Suspected tension pneumothorax AND Critically ill OR VSA AND Absent or severely diminished breath sounds on the affected side(s) Conditions N/A LOA: N/A HR: N/A RR: N/A SBP: Hypotension or VSA ACP Needle Thoracostomy AGE: Other: N/A Contraindications Needle Thoracostomy Special Events N/A Treatment MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to perform needle thoracostomy Consider needle thoracostomy Clinical Considerations Notes Needle thoracostomy may only be performed at the second intercostal space in the midclavicular line. ACP Medical Directives 53 Pain Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Severe pain AND Isolated hip or extremity fractures or dislocations OR major burns OR current history of cancer related pain OR renal colic with prior history OR patients with acute musculoskeletal back strain OR ongoing transcutaneous pacing Conditions Morphine Fentanyl AGE: ≥18 years AGE: ≥18 years LOA: Unaltered LOA: Unaltered HR: N/A HR: N/A RR: N/A RR: N/A SBP: Normotension SBP: Normotension Other: N/A Other: N/A Contraindications Fentanyl Allergy or sensitivity to fentanyl Allergy or sensitivity to morphine Injury to the head or chest or abdomen or pelvis Injury to the head or chest or abdomen or pelvis SBP drops by one-third or more of its initial value SBP drops by one-third or more of its initial value ACP Medical Directives 54 Morphine Intro Treatment Consider fentanyl OR morphine: Drug Morphine Route IV 2–5mg Max. single dose 50 mcg 5 mg Dosing interval 5 min. 5 min. Max. # of doses 4 4 PCP Dose Drug Fentanyl Route IV 25–50 mcg Clinical Considerations Notes Special Events ACP N/A ACP Medical Directives 55 Pediatric Pain Medical Directive An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications Severe pain AND Isolated hip OR extremity fractures or dislocations OR major burns OR current history of cancer related pain Conditions Morphine AGE: <18 years LOA: Unaltered HR: >60/min RR: N/A SBP: Age Related Normotension Contraindications Morphine Allergy or sensitivity to morphine Injury to the head or chest or abdomen or pelvis SBP drops by one-third or more of its initial value ACP Medical Directives 56 Intro MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization and dosage verification before administering the medication for children <8 years. Treatment Consider morphine: Max. single dose 3 mg Dosing interval 5 min. Max. # of doses 2 PCP Dose Route IV/SC 0.05mg/kg ACP Clinical Considerations Notes Special Events N/A ACP Medical Directives 57 Adult Intraosseous Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Actual or potential need for intravenous medication OR fluid therapy AND IV access is unobtainable AND Cardiac arrest OR near arrest state Conditions IO AGE: ≥12 years LOA: N/A HR: N/A RR: N/A SBP: N/A Other: N/A Contraindication IO Fracture or crush injuries or suspected or known replacement / prosthesis proximal to the access site. Treatment Consider IO access Clinical Considerations N/A ACP Medical Directives 58 Intro Central Venous Access Device Access Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications PCP Actual or potential need for intravenous medication OR fluid therapy AND IV access is unobtainable AND Cardiac arrest OR near arrest state Conditions AGE: N/A LOA: N/A HR: N/A RR: N/A SBP: N/A Other: ACP CVAD Access Patient has a pre-existing, accessible central venous catheter in place Special Events Contraindications CVAD Access N/A Treatment Consider CVAD access Clinical Considerations Notes N/A ACP Medical Directives 59 Continuous Positive Airway Pressure (CPAP) Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Severe respiratory distress AND Signs and/or symptoms of acute pulmonary edema OR COPD Conditions CPAP AGE: ≥18 years LOA: N/A HR: N/A RR: Tachypnea SBP: Normotension Other: SpO2 <90% or accessory muscle use Contraindications CPAP Asthma exacerbation Suspected pneumothorax Unprotected or unstable airway Major trauma or burns to the head or torso Tracheostomy Inability to sit upright Unable to cooperate ACP Medical Directives 60 Intro Treatment Consider CPAP: Titration increment Titration interval Max. setting 5 cm H2O Or equivalent flow rate of device as per BH direction 2.5 cm H2O Or equivalent flow rate of device as per BH direction 5 min. 15 cm H2O Or equivalent flow rate of device as per BH direction PCP Initial setting Consider increasing FiO2 (if available): 50–100% FiO2 increment (if available on device) SpO2 <92% despite treatment and/or 10cm H2O pressure or equivalent flow rate of device as per BH direction Max FiO2 100% ACP Initial FiO2 Confirm CPAP pressure by manometer (if available) Clinical Considerations Notes Special Events N/A ACP Medical Directives 61 Supraglottic Airway Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Need for ventilatory assistance OR airway control AND Other airway management is inadequate OR ineffective OR unsuccessful Conditions Supraglottic Airway AGE: N/A LOA: GCS = 3 HR: N/A RR: N/A SBP: N/A Other: Absent gag reflex Contraindications Supraglottic Airway Active vomiting Inability to clear the airway Airway edema Stridor Caustic ingestion ACP Medical Directives 62 Intro Treatment Consider supraglottic airway insertion: The maximum number of attempts is 2. Confirm supraglottic airway placement: Method Secondary ETCO2 Other PCP Method Primary Auscultation Chest rise Clinical Considerations An attempt at supraglottic airway insertion is defined as the insertion of the supraglottic airway into the mouth. Notes Special Events ACP The maximum number of supraglottic airway attempts is two (2) and the maximum number of intubation attempts is two (2). ACP Medical Directives 63 Cricothyrotomy Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Need for advanced airway management AND Intubation AND supraglottic airway (if available) insertion unsuccessful or contraindicated AND Unable to ventilate Conditions Cricothyrotomy AGE: ≥12 years LOA: Altered HR: N/A RR: N/A SBP: N/A Other: N/A Contraindications Cricothyrotomy Suspected fractured larynx Inability to landmark ACP Medical Directives 64 Intro Treatment MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to perform cricothyrotomy Consider cricothyrotomy. Confirm cricothyrotomy: tube placement Method Secondary ETCO2 Other PCP Method Primary Auscultation Chest rise Clinical Considerations At least two primary and one secondary Cricothyrotomy tube placement confirmation methods must be used. ACP If the patient has a pulse, an ETCO2 device must be used (quantitative or qualitative) for cricothyrotomy tube placement confirmation. Additional secondary Cricothyrotomy tube placement confirmation devices may be authorized by the local medical director. Notes Special Events Cricothyrotomy tube placement must be reconfirmed immediately after every patient movement. ACP Medical Directives 65 Nausea / Vomiting Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Nausea OR vomiting Conditions Dimenhydrinate AGE: N/A LOA: Unaltered HR: N/A RR: N/A SBP: N/A Other: N/A Contraindications Dimenhydrinate Allergy or sensitivity to dimenhydrinate or other antihistamines Overdose on antihistamines or anticholinergics or TCAs ACP Medical Directives 66 Intro Treatment Dose Weight Weight Weight <25 kg ≥25 kg to <50 kg ≥50 kg Route Route Route Route Route Route IV IM IV IM IV IM Patch Patch 25mg 25mg 50mg 50mg Max. single dose N/A N/A 25mg 25mg 50mg 50mg Dosing interval N/A N/A N/A N/A N/A N/A Max. # of doses N/A N/A 1 1 1 1 PCP Consider dimenhydrinate: Clinical Considerations Notes Special Events ACP Prior to IV administration, dilute dimenhydrinate (concentration of 50 mg/1 ml) 1:9 with Normal Saline or sterile water. If given IM do not dilute. ACP Medical Directives 67 Combative Patient Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Combative patient Conditions Midazolam AGE: ≥18 years LOA: N/A HR: N/A RR: N/A SBP: Normotension Other: No reversible causes (i.e. hypoglycemia, hypoxia, hypotension) Contraindications Midazolam Allergy or sensitivity to midazolam Treatment MANDATORY PROVINCIAL PATCH POINT: Patch to BHP for authorization to proceed with midazolam if unable to assess the patient for normotension or reversible causes. ACP Medical Directives 68 Route IM 2.5–5 mg 5 mg Dosing interval 5 min. 5 min. Max. total dose 10 mg 10 mg 2 2 Dose Max. single dose Max. # doses PCP Route IV 2.5–5 mg 5 mg Intro Consider midazolam: Clinical Considerations Notes Special Events ACP N/A ACP Medical Directives 69 Procedural Sedation Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Post-intubation OR transcutaneous pacing Conditions Midazolam AGE: ≥18 years LOA: N/A HR: N/A RR: ≥ 8 bpm* SBP: Normotension Other: N/A *Non-intubated patients only Contraindications Midazolam Allergy or sensitivity to midazolam ACP Medical Directives 70 Intro Treatment Consider midazolam: Route IV 2.5–5 mg Max. single dose 5 mg Dosing interval 5 min. Max. total dose 10 mg Max. # doses 2 PCP Dose Clinical Considerations Notes Special Events ACP N/A ACP Medical Directives 71 Electronic Control Device Probe Removal Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Electronic Control Device probe(s) embedded in patient. Conditions Probe Removal AGE: ≥18 years LOA: Unaltered HR: N/A RR: N/A SBP: N/A Other: N/A Contraindications Probe removal Probe embedded above the clavicles, in the nipple(s), or in the genital area Treatment Consider probe removal Clinical Considerations Police may require preservation of the probe(s) for evidentiary purposes. This directive is for removal of ECD only and in no way constitutes treat and release, normal principles of patient assessment and care apply. ACP Medical Directives 72 Intro Analgesia Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Isolated Hip OR Extremity Trauma AND Pain Conditions Acetaminophen ≥ 18 years AGE: ≥ 18 and < 50 years LOA: Unaltered LOA: Unaltered HR: N/A HR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A Other: N/A Other: N/A ACP AGE: PCP Ibuprofen Contraindications Acetaminophen Ibuprofen Acetaminophen use within previous 4 hours Ibuprofen or NSAID use within previous 6 hours Allergy or sensitivity to acetaminophen Active vomiting Signs or symptoms of intoxication Major burns Major burns Hx of liver disease Special Events Current active bleeding Hx of peptic ulcer disease or GI bleed Pregnant Hx cardiovascular disease If asthmatic, no prior use of ASA or other NSAIDs CVA or TBI in the previous 24 hours Notes Active vomiting Allergy or sensitivity to ASA or NSAIDS ACP Medical Directives 73 Treatment Consider acetaminophen: Route PO Dose Max. single dose 960–1000 mg 1000 mg Dosing interval N/A Max. # of doses 1 Consider ibuprofen: Route PO Dose 400 mg Max. single dose 400 mg Dosing interval N/A Max. # of doses 1 Clinical Considerations Whenever possible, both acetaminophen and ibuprofen should be used together. This medical directive does not replace the ACP Core Pain Medical Directive and may be used in conjunction where appropriate. ACP Medical Directives 74 Intro Moderate to Severe Pain Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications PCP Moderate to Severe pain AND Isolated hip or extremity trauma OR major burns OR current history of cancer related pain OR renal colic with prior history OR patients with acute musculoskeletal back strain. Conditions AGE: ≥ 18 years and < 50 years LOA: Unaltered HR: N/A RR: N/A SBP: Normotension Other: Patient must remain NPO or is unable to take oral medications ACP Ketorolac Contraindications Special Events Ketorolac NSAID or ibuprofen use within previous 6 hours Allergy or sensitivity to ASA or NSAIDs Patient on anticoagulation therapy Current active bleeding CVA or TBI in the previous 24 hours If asthmatic, no prior use of ASA or other NSAIDs Pregnant Notes Known renal impairment ACP Medical Directives 75 Treatment Consider ketorolac: Route IM/IV Dose 30 mg Max. single dose 30mg Dosing interval N/A Max. # of doses 1 Clinical Considerations This medical directive does not replace the ACP Core Pain Medical Directive and may be used in conjunction where appropriate. ACP Medical Directives 76 Intro Nasotracheal Intubation Medical Directive – AUXILIARY An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized. Indications PCP Need for ventilatory assistance or airway control AND Other airway management is inadequate or ineffective Conditions Lidocaine Spray Nasotracheal Intubation N/A AGE: N/A AGE: ≥ 8 years LOA: N/A LOA: N/A LOA: N/A HR: N/A HR: N/A HR: N/A RR: N/A RR: N/A RR: N/A SBP: N/A SBP: N/A SBP: N/A Other: Nasotracheal intubation Other: Nasotracheal Intubation Other: Spontaneous Breathing Notes Special Events AGE: ACP Xylometazoline ACP Medical Directives 77 Contraindications Nasotracheal Intubation Lidocaine Xylometazoline Allergy or sensitivity to xylometazoline Age < 50 years AND current episode of asthma exacerbation AND not in or near cardiac arrest Allergy or sensitivity to lidocaine Unresponsive patient Suspected basal skull fracture or mid-face fracture Uncontrolled epistaxis Anticoagulant therapy (excluding ASA) Bleeding disorders Treatment Consider xylometazoline 0.1% spray: for nasotracheal intubation Dose Route TOPICAL 2 sprays/nare Max. single dose 2 sprays/nare Dosing interval N/A Max. # of doses 1 ACP Medical Directives 78 Intro Consider topical lidocaine spray for “awake” orotracheal or nasotracheal intubation (to nares and/or hypopharynx): Route TOPICAL Dose 10 mg/spray 5mg/kg N/A 20 sprays PCP Max. dose Dosing interval Max. # of doses Consider intubation: The maximum number of intubation attempts is 2. Method Primary Method Secondary Visualization ETCO2 Auscultation Chest rise EDD Other ACP Confirm nasotracheal tube placement: Clinical Considerations An intubation attempt is defined as insertion of the ETT into a nare. Special Events The maximum number of supraglottic airway attempts is two (2) and the maximum number of intubation attempts is two (2). At least two primary and one secondary ETT placement confirmation methods must be used. An ETCO2 device (quantitative or qualitative) must be used for ETT placement confirmation. Additional secondary ETT placement confirmation devices may be authorized by the local medical director. Notes ETT placement must be reconfirmed immediately after every patient movement. ACP Medical Directives 79 Page Left Blank Intentionally ACP Medical Directives 80 Intro PCP Notes Special Events ACP Page Left Blank Intentionally ACP Medical Directives 81 Page Left Blank Intentionally ACP Medical Directives 82 Intro PCP Notes Special Events ACP Page Left Blank Intentionally ACP Medical Directives 83 Page Left Blank Intentionally ACP Medical Directives 84 Intro PCP ACP Notes Special Events SPECIAL EVENTS MEDICAL DIRECTIVES Special Events Medical Directives Special Events Medical Directives Table of Contents Minor Abrasions Medical Directive – AUXILIARY ........................................................................ 3 Minor Allergic Reactions Medical Directive – AUXILIARY .......................................................... 4 Musculoskeletal Pain Medical Directive – AUXILIARY ................................................................ 6 Headache Medical Directive – AUXILIARY ..................................................................................... 8 Blank page left for future Medical Directives .......................................................................... 10 Special Events Medical Directives 2 Intro Minor Abrasions Medical Directive – auxiliary A Primary Care Paramedic or Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Minor abrasions AND Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director PCP Conditions AGE: N/A LOA: Unaltered HR: N/A RR: N/A SBP: N/A Other: N/A ACP Topical Antibiotic Contraindications Topical Antibiotic Special Events Allergy or sensitivity to any of the components of the topical antibiotic Treatment Consider topical antibiotic Consider release from care Clinical Considerations Notes Advise patient that if the problem persists or worsens that they should seek further medical attention. Special Events Medical Directives 3 Minor Allergic Reaction Medical Directive – auxiliary A Primary Care Paramedic or Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Signs consistent with minor allergic reaction AND Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director Conditions Diphenhydramine AGE: ≥18 years LOA: Unaltered HR: WNL RR: WNL SBP: Normotension Other: N/A Contraindications Diphenhydramine Allergy or sensitivity to diphenhydramine Antihistamine or sedative use in previous 4 hours Signs or symptoms of moderate to severe allergic reaction Signs or symptoms of intoxication Wheezing Special Events Medical Directives 4 Intro Treatment Consider diphenhydramine: Dose Max. single dose Dosing interval Max. # of doses Route PO 50 mg 50 mg N/A 1 PCP Consider release from care Clinical Considerations Notes Special Events ACP Advise patient that if the problem persists or worsens that they should seek further medical attention. Special Events Medical Directives 5 Musculoskeletal Pain Medical Directive – auxiliary A Primary Care Paramedic or Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Minor musculoskeletal pain AND Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director Conditions Acetaminophen AGE: ≥18 years LOA: Unaltered HR: N/A RR: N/A SBP: N/A Other: N/A Contraindications Acetaminophen No acetaminophen in the last 4 hours Allergy or sensitivity to acetaminophen Signs or symptoms of intoxication Special Events Medical Directives 6 Intro Treatment Consider acetaminophen: Dose Max. single dose Dosing interval Max. # of doses Route PO 325–650 mg 650 mg N/A 1 PCP Consider release from care Clinical Considerations Notes Special Events ACP Advise patient that if the problem persists or worsens that they should seek further medical attention. Special Events Medical Directives 7 Headache Medical Directive – auxiliary A Primary Care Paramedic or Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized. Indications Uncomplicated headache conforming to the patient’s usual pattern AND Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director Conditions Acetaminophen AGE: ≥18 years LOA: Unaltered HR: N/A RR: N/A SBP: N/A Other: N/A Contraindications Acetaminophen No acetaminophen in past 4 hours Allergy or sensitivity to acetaminophen Signs or symptoms of intoxication Special Events Medical Directives 8 Intro Treatment Consider acetaminophen: Dose Max. single dose Dosing interval Max. # of doses Route PO 325–650 mg 650 mg N/A 1 PCP Consider release from care Clinical Considerations Notes Special Events ACP Advise patient that if the problem persists or worsens that they should seek further medical attention. Special Events Medical Directives 9 Page Left Blank Intentionally Special Events Medical Directives 10 Notes Special Events ACP PCP NOTES Notes Intro Notes 2 Notes 3 Notes Special Events ACP PCP Intro Notes 4 Notes 5 Notes Special Events ACP PCP Intro Notes 6
